Fragile X-Associated Primary Ovarian Insufficiency

Mendelian MONDO:0010706 Pathograph 14 Show in embeddings browser Trinucleotide Repeat Disorder Primary Ovarian Insufficiency

Fragile X-associated primary ovarian insufficiency (FXPOI; OMIM premature ovarian failure 1, POF1) is the ovarian disorder of FMR1 premutation carriers (55-200 CGG repeats in the FMR1 5' UTR). It is one of the three recognized FMR1 disorders, alongside full-mutation fragile X syndrome (FXS) and the premutation neurodegenerative disorder FXTAS. FXPOI is defined as hypergonadotropic hypogonadism before age 40 and is observed in about 20% of female premutation carriers, compared with about 1% of the general population; a larger fraction show subclinical ("occult") ovarian insufficiency with declining ovarian reserve before FSH crosses the diagnostic threshold. Like FXTAS, and unlike FXS, FXPOI is a premutation phenotype: the expanded allele largely escapes methylation-mediated silencing and is transcribed at elevated levels, so pathogenesis is attributed to a toxic gain-of-function of the expanded CGG-repeat FMR1 mRNA, with a proposed parallel contribution from repeat-associated non-AUG (RAN) translation of the polyglycine protein FMRpolyG, rather than to loss of FMRP. Ovarian consequences are granulosa cell dysfunction and accelerated depletion of the follicle pool, giving menstrual irregularity, subfertility, early menopause, and the long-term sequelae of premature estrogen deficiency (bone loss, cardiovascular risk, vasomotor symptoms, psychosocial burden). Because intermittent ovulatory function can persist after diagnosis, FXPOI is described as an insufficiency rather than an absolute failure.

Ask OpenScientist

Ask a research question about Fragile X-Associated Primary Ovarian Insufficiency. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
8
Pathophys.
11
Phenotypes
1
Hypotheses
2
Gaps
14
Pathograph
1
Genes
1
Variants
6
Medical Actions
3
Differentials
1
References
1
Deep Research
🏷

Classifications

Harrison's Part
ENDOCRINOLOGY METABOLISM GENETICS ENVIRONMENT DISEASE
👪

Inheritance

1
X-linked inheritance HP:0001417
FXPOI is transmitted in an X-linked manner via FMR1 premutation alleles. Penetrance is incomplete: roughly 20% of heterozygous female premutation carriers develop hypergonadotropic hypogonadism before age 40, and expressivity ranges from subclinical diminished ovarian reserve to overt amenorrhea. Male premutation carriers do not manifest FXPOI but transmit the premutation to all of their daughters, who are then at risk.
X-linked inheritance Penetrance: INCOMPLETE Expressivity: VARIABLE
Show evidence (2 references)
PMID:20301558 SUPPORT Other
"FMR1 disorders are inherited in an X-linked manner."
GeneReviews establishes X-linked inheritance for the FMR1 disorders, including FXPOI.
PMID:20301558 SUPPORT Other
"Males with FXTAS will transmit their FMR1 premutation expansion to all of their daughters, who will be heterozygous for a premutation and at increased risk for FXTAS, FXPOI, and FXAND."
Documents the X-linked transmission pattern specific to FXPOI risk, including the obligate transmission from premutation-carrier fathers to all daughters.
◈

Mechanistic Hypotheses

1
Canonical FMR1 Premutation RNA Gain-of-Function (± RAN-Translation) Model of Ovarian Toxicity
canonical_fmr1_premutation_ovarian_rna_gof_model CANONICAL
Evidence balance 2 support
FXPOI is attributed to the same premutation gain-of-function paradigm established for FXTAS, applied to the ovary. The 55-200 CGG premutation allele largely escapes the hypermethylation that silences the full mutation, is transcribed at elevated levels, and the expanded CGG-repeat FMR1 mRNA is itself toxic - forming nuclear RNA foci that sequester CGG-repeat-binding proteins away from their normal functions. A parallel, non-exclusive arm is repeat-associated non-AUG (RAN) translation of the expanded repeat into an aggregation-prone polyglycine protein, FMRpolyG. In the ovary these converge on granulosa cell dysfunction and death and on accelerated depletion of the follicle pool, producing hypergonadotropic hypogonadism before age 40. Note the directional contrast with FXS, where >200 repeats silence FMR1 and disease arises from loss of FMRP: FXPOI is not an FMRP-deficiency phenotype.
Show evidence (2 references)
PMID:17618523 SUPPORT INDIRECT Human Clinical
"The pathogenic mechanism is related to overexpression and toxicity of the FMR1 mRNA per se."
Establishes the FMR1 mRNA toxic gain-of-function paradigm for premutation disease. Graded INDIRECT because this statement is made for FXTAS; its extension to the ovarian phenotype is an inference from the shared premutation genotype rather than a direct ovarian observation in this paper.
PMID:25954027 SUPPORT In Vitro
"the repeat also elicits production of a toxic polyglycine protein, FMRpolyG, via repeat-associated non-AUG (RAN)-initiated translation"
Supplies the RAN-translation/FMRpolyG arm of the premutation gain-of-function model. The experiments are Drosophila and transfected-cell models of FXTAS, not ovarian tissue.
?

Discussions and Knowledge Gaps

2
By what intermediate steps does sequestration of CGG-repeat-binding proteins in granulosa cells lead to loss of the ovarian follicle, and does FMRpolyG add anything to the RNA arm that is already sufficient to kill granulosa cells?
KNOWLEDGE GAP OPEN fxpoi_ovarian_mechanism_evidence_gap
Attached to
pathophysiology#RNA gain-of-function and sequestration of CGG-repeat-binding proteins pathophysiology#RAN translation and FMRpolyG production pathophysiology#Granulosa cell dysfunction and death pathophysiology#Accelerated ovarian follicle depletion
The question of whether the FXTAS RNA-toxicity paradigm operates in granulosa cells at all is now substantially answered: an in vitro granulosa cell model shows expanded CGG-repeat RNA aggregating intranuclearly and killing granulosa cells, and a premutation mouse shows the corresponding RNA-binding proteins depleted in ovarian follicles. What remains open is the chain in between - which sequestered protein, acting on which granulosa function, translates into loss of a follicle - and whether FMRpolyG contributes anything additive, given that granulosa cell death does not require it. Three of the four nodes on this arm stay PROVISIONAL, for two different reasons: the RNA and RAN nodes because their direct evidence is still FXTAS-derived, and the granulosa node because its evidence, though ovarian, comes from an ectopic-expression cell model and from mice rather than from carriers. Only the follicle-depletion node is ESTABLISHED, since accelerated loss of ovarian reserve in premutation carriers is itself a clinical observation.
Proposed experiments
Repeat-RNA foci and FMRpolyG in premutation-carrier granulosa cells
exp_fxpoi_granulosa_foci_fmrpolyg
Assay granulosa cells recovered from FMR1 premutation carriers undergoing assisted reproduction for CGG-repeat RNA foci and FMRpolyG, and relate their burden to contemporaneous ovarian reserve markers (AMH, antral follicle count) and repeat length.
Supporting outcome
  • Detection of foci and FMRpolyG in granulosa cells recovered from premutation carriers themselves, scaling with repeat length and inversely with ovarian reserve, would replace the current ectopic-expression and mouse support with patient-derived evidence and justify moving the granulosa node from PROVISIONAL to ESTABLISHED.
Refuting outcome
  • Absence of foci and FMRpolyG in granulosa cells of affected carriers would argue that the ovarian lesion is not a direct transposition of the neuronal mechanism.
Separating RNA toxicity from RAN translation in granulosa cells
exp_fxpoi_ran_translation_dissection
In cultured human granulosa cells expressing premutation-length CGG repeats, block RAN translation without altering repeat-RNA abundance, and separately reduce repeat-RNA abundance while preserving FMRpolyG output, then measure cell viability.
Supporting outcome
  • Rescue on repeat-RNA reduction alone would establish RNA gain-of-function as the dominant ovarian arm.
Refuting outcome
  • Rescue only when FMRpolyG is blocked would reassign the ovarian mechanism to the RAN-translation arm.
Why is FXPOI risk non-linear in repeat length, rising through the mid-premutation range and then falling at the largest premutation sizes?
OPEN QUESTION OPEN fxpoi_nonlinear_repeat_size_risk
Attached to
pathophysiology#FMR1 premutation CGG expansion and elevated FMR1 mRNA
A purely dose-dependent RNA-toxicity model predicts that risk should rise monotonically with repeat length. The observed decline in risk at the largest premutation sizes is therefore a genuine constraint on the mechanism rather than a detail. The effect itself is no longer in question - it is curated in the genetic section on PMID:33927378, a 1,668-carrier cohort - so what stays open here is the explanation, not the observation. The causal chain as curated has no node that would produce an inverted-U, and the usual proposal, that rising repeat-RNA burden is offset by falling translational output at the largest repeat sizes, has not been measured against ovarian outcome in the same carriers.
Proposed experiments
Repeat-length-stratified FMR1 mRNA, FMRP, and FMRpolyG versus ovarian reserve
exp_fxpoi_repeat_length_stratified_molecular_profile
In a carrier cohort stratified across the premutation range, measure FMR1 mRNA level, FMRP level, and FMRpolyG burden in the same individuals and relate each to ovarian reserve, testing whether declining FMRP or translational output at the largest repeat sizes offsets rising repeat-RNA burden.
Supporting outcome
  • An inverted-U in a composite toxicity measure that tracks the clinical risk curve would explain the non-linearity within the current model.
Refuting outcome
  • A monotonic molecular gradient across repeat lengths would indicate that the non-linear clinical risk arises outside the RNA-toxicity axis.
⚙

Pathophysiology

8
FMR1 premutation CGG expansion and elevated FMR1 mRNA
The initiating lesion is a premutation-range (55-200 CGG) trinucleotide repeat expansion in the FMR1 5' UTR at Xq27.3. Unlike the full mutation (>200 repeats), which is hypermethylated and transcriptionally silenced, the premutation allele remains largely unmethylated and is actively transcribed, producing elevated levels of an FMR1 mRNA carrying the expanded CGG tract. This transcript, not the loss of FMRP, is the proximate pathogenic species.
FMR1 hgnc:3775 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves increased FMR1 (hgnc:3775). hgnc:3775 is a gene from the HUGO Gene Nomenclature Committee. ↑ INCREASED
gene expression GO:0010467 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased gene expression (GO:0010467). GO:0010467 is a biological process from the Gene Ontology. ↑ INCREASED
ovary UBERON:0000992 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in ovary (UBERON:0000992). UBERON:0000992 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
RNA gain-of-function and sequestration of CGG-repeat-binding proteins The elevated expanded-repeat transcript forms the nuclear RNA species that binds and sequesters CGG-repeat-binding proteins.
RAN translation and FMRpolyG production The same expanded CGG tract in the transcript is the substrate for repeat-associated non-AUG translation.
Show evidence (2 references)
PMID:20301558 SUPPORT Other
"the diagnosis of FXTAS or FXPOI is associated with a premutation-sized repeat (55-200 CGG repeats)"
GeneReviews anchors FXPOI to the premutation repeat range rather than the full mutation.
PMID:17618523 SUPPORT Human Clinical
"moderate expansions (55-200 repeats; premutation range) of a CGG trinucleotide in the fragile X mental retardation 1 (FMR1) gene, the same gene which causes fragile X syndrome when in the full mutation range (200 or greater CGG repeats)"
Defines the premutation repeat range and its contrast with the full mutation at the same locus, the genetic basis of this node.
RNA gain-of-function and sequestration of CGG-repeat-binding proteins
The expanded CGG-repeat FMR1 mRNA forms nuclear RNA aggregates that bind and sequester CGG-repeat-binding proteins - identified in FXTAS models as Pur alpha and hnRNP A2/B1 - depleting them from their normal functions. This is the leading arm of premutation toxicity. The direct ovarian evidence is thinner than the neuronal evidence from FXTAS models; its application to granulosa cells is an extension of the shared premutation mechanism rather than a directly demonstrated ovarian finding.
Downstream
Granulosa cell dysfunction and death Sequestration of RNA-binding proteins is proposed to impair the somatic support cells of the follicle, but the intermediate steps are not established in the human ovary.
Show evidence (3 references)
PMID:17698009 SUPPORT Model Organism
"transcribed premutation repeats alone are sufficient to cause neurodegeneration, suggesting that rCGG-repeat-binding proteins (RBPs) may be sequestered from their normal function by rCGG binding"
Provides the mechanistic basis for RNA-mediated protein sequestration by premutation transcripts. The model is Drosophila neurons, not ovarian tissue.
PMID:25954027 SUPPORT In Vitro
"FXTAS is thought to arise primarily from an RNA gain-of-function toxicity mechanism."
States the primacy of the RNA gain-of-function route among premutation mechanisms. The claim is framed for FXTAS.
PMID:36250920 SUPPORT In Vitro
"identified proteins that are specifically sequestered by CGG RNA aggregates in granulosa cells in vitro"
Shows the sequestration step asserted by this node occurring in granulosa cells specifically, rather than only in the neuronal FXTAS models. The node is nonetheless held at PROVISIONAL because which sequestered protein is functionally decisive for the follicle remains open.
RAN translation and FMRpolyG production
Repeat-associated non-AUG (RAN) translation initiates within the expanded CGG tract and produces an aggregation-prone polyglycine protein, FMRpolyG. This is the parallel protein-toxicity arm of the premutation mechanism, and the evidence that it is initiated at all comes from FXTAS models rather than ovarian tissue. Its standing in the ovary is now constrained rather than simply open: in the granulosa cell model, expanded CGG-repeat RNA causes cell death independently of FMRpolyG, so the RNA arm is sufficient for the granulosa lesion and FMRpolyG is not required for it. What remains unresolved is whether FMRpolyG makes any additional contribution to FXPOI on top of the RNA arm - not whether the RNA arm needs it.
regulation of translation GO:0006417 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal regulation of translation (GO:0006417). GO:0006417 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Granulosa cell dysfunction and death FMRpolyG may contribute to granulosa cell injury, but it is demonstrably not required for it: granulosa cell death occurs independently of FMRpolyG expression. This edge is therefore retained as a possible additive contribution, not a necessary step.
Show evidence (1 reference)
PMID:25954027 SUPPORT In Vitro
"the repeat also elicits production of a toxic polyglycine protein, FMRpolyG, via repeat-associated non-AUG (RAN)-initiated translation"
Establishes RAN translation of FMRpolyG from the expanded CGG repeat. The models are Drosophila and transfected mammalian cells studied for FXTAS.
Granulosa cell dysfunction and death
The cellular lesion is in the granulosa cells that support the developing follicle: dysregulated folliculogenesis signaling (including altered AMH output) and granulosa cell death. Granulosa cells, not oocytes, are the cell type in which premutation toxicity has been most directly implicated. The node is held at PROVISIONAL rather than ESTABLISHED because its support, while genuinely ovarian, comes entirely from an ectopic-expression granulosa cell model plus premutation mice - there is no observation in granulosa cells from premutation carriers themselves. The attached KNOWLEDGE_GAP discussion records what would close that.
granulosa cell CL:0000501 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves granulosa cell (CL:0000501). CL:0000501 is a cell type from the Cell Ontology.
apoptotic process GO:0006915 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased apoptotic process (GO:0006915). GO:0006915 is a biological process from the Gene Ontology. ↑ INCREASED
ovary UBERON:0000992 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in ovary (UBERON:0000992). UBERON:0000992 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Accelerated ovarian follicle depletion Loss of granulosa cell support accelerates the attrition of follicles from the ovarian reserve.
Show evidence (3 references)
PMID:36250920 SUPPORT In Vitro
"we have developed an in vitro granulosa cell model of the FMR1 premutation by ectopically expressing CGG-repeat RNA and FMRpolyG protein. We show that expanded CGG-repeat RNA accumulated in intranuclear RNA structures, and these aggregates were able to cause significant granulosa cell death..."
Direct ovarian-cell evidence that expanded CGG-repeat RNA kills granulosa cells, and that it does so independently of FMRpolyG - establishing the RNA arm as sufficient for the granulosa lesion.
PMID:36250920 SUPPORT Model Organism
"reduced expression of three proteins ... FUS, PA2G4 and TRA2β ... in ovarian follicles in a FMR1 premutation mouse model"
Extends the sequestration finding from cultured granulosa cells into ovarian follicles in vivo, naming the depleted RNA-binding proteins.
PMID:22470123 SUPPORT Model Organism
"PM follicles are smaller and have fewer granulosa cells (GCs) than normal."
Independent in vivo confirmation that the granulosa compartment is depleted in premutation ovaries.
Accelerated ovarian follicle depletion
The tissue-level consequence is faster-than-normal attrition of the ovarian follicle pool. The reserve is established normally and puberty proceeds normally; it is the subsequent rate of loss that is abnormal, which is why FXPOI presents as premature reproductive aging rather than as a congenital gonadal dysgenesis. An additional mechanism proposed from Fmr1 mouse work - premature mTOR-driven recruitment of primordial follicles, i.e. accelerated burn-through of the reserve rather than increased death alone - is noted here but not asserted as an evidence-backed node (see notes).
oocyte CL:0000023 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves oocyte (CL:0000023). CL:0000023 is a cell type from the Cell Ontology.
ovarian follicle development GO:0001541 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal ovarian follicle development (GO:0001541). GO:0001541 is a biological process from the Gene Ontology. ⚠ ABNORMAL
ovary UBERON:0000992 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in ovary (UBERON:0000992). UBERON:0000992 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Hypergonadotropic hypogonadism Loss of the follicle pool removes the ovarian source of estradiol and of the inhibin/AMH feedback signals to the pituitary.
Show evidence (1 reference)
PMID:22470123 SUPPORT Model Organism
"the gross development of the ovary and the establishment of the primordial follicle pool is normal in these mice. However, these animals show a faster loss of follicles of all follicle classes, suggesting that the problem is intrinsic to the ovary."
Directly supports this node's specific claim - that the reserve is established normally and it is the subsequent attrition rate that is abnormal - and localizes the lesion to the ovary itself rather than to central endocrine control.
Hypergonadotropic hypogonadism
Depletion of the follicle pool removes ovarian estradiol and inhibin output, releasing the pituitary from negative feedback and producing menopausal-range FSH with low estradiol before age 40 - the defining endocrine state of FXPOI. Ovarian function is not always absolutely lost: intermittent ovulatory activity may persist, so spontaneous conception after diagnosis is unlikely but not impossible.
Downstream
Chronic estrogen deficiency Sustained hypoestrogenism from an age decades before typical menopause drives the long-term morbidity of FXPOI.
Show evidence (2 references)
PMID:20301558 SUPPORT Other
"FXPOI, defined as hypergonadotropic hypogonadism before age 40 years, has been observed in 20% of women who carry a premutation allele compared to 1% in the general population"
GeneReviews defines FXPOI by this endocrine state and quantifies its excess over the general population.
PMID:38677871 SUPPORT INDIRECT Human Clinical
"This review focuses on primary amenorrhea and primary/premature ovarian insufficiency due to hypergonadotropic hypogonadism."
Confirms hypergonadotropic hypogonadism as the endocrine mechanism of premature ovarian insufficiency generally. Graded INDIRECT because the review is about POI as a class, not FXPOI specifically.
Chronic estrogen deficiency
Premature and prolonged estrogen deficiency is the source of the non-reproductive morbidity of FXPOI: vasomotor symptoms, accelerated bone loss with reduced bone mineral density, adverse cardiovascular risk, and effects on quality of life. This is the rationale for hormone therapy continued to the age of typical natural menopause, and it is shared with primary ovarian insufficiency of any cause rather than being specific to the FMR1 premutation.
Downstream
Estrogen-deficiency bone remodeling imbalance Loss of estrogen uncouples bone resorption from formation, the entry point of the conserved osteoporosis mechanism.
Show evidence (1 reference)
PMID:39647506 SUPPORT Human Clinical
"The potential implications include adverse effects on quality of life, on fertility and on bone, cardiovascular and cognitive health. Although hormone therapy (HT) can mitigate some of these effects, many questions still remain regarding the optimal management of POI."
The 2024 international POI guideline enumerates the sequelae of premature estrogen deficiency and the mitigating role of hormone therapy. It addresses POI as a class rather than the FMR1 premutation subtype.
Estrogen-deficiency bone remodeling imbalance
Premature loss of ovarian estrogen uncouples osteoclastic resorption from osteoblastic formation, which is the initiating lesion of the conserved osteoporosis mechanism. The downstream chain (RANKL-driven osteoclastogenesis, increased resorption, net bone loss) is not duplicated here; this node declares conformance to the shared module instead. The driver is hormonal, which is precisely the case the module's trigger node is written to accommodate.
Show evidence (1 reference)
PMID:39647506 SUPPORT Human Clinical
"The potential implications include adverse effects on quality of life, on fertility and on bone, cardiovascular and cognitive health."
Establishes bone as an affected system in POI. The guideline states the clinical consequence rather than the remodeling-imbalance mechanism, which is carried by the conformance to the osteoporosis module.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Fragile X-Associated Primary Ovarian Insufficiency Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

11
Endocrine 2
Hypergonadotropic hypogonadism HP:0000815 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypergonadotropic hypogonadism (HP:0000815). HP:0000815 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301558 SUPPORT Other
"FXPOI, defined as hypergonadotropic hypogonadism before age 40 years"
GeneReviews makes hypergonadotropic hypogonadism definitional for FXPOI.
Delayed puberty HP:0000823 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed puberty (HP:0000823). HP:0000823 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38677871 SUPPORT Human Clinical
"Pubertal induction and ongoing estrogen replacement therapy are often necessary."
Establishes that hypergonadotropic ovarian insufficiency can present before puberty is complete and require pubertal induction. The review covers POI as a class and does not quantify this presentation in FMR1 premutation carriers.
Genitourinary 3
Premature ovarian insufficiency OCCASIONAL HP:0008209 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Premature ovarian insufficiency (HP:0008209). HP:0008209 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301558 SUPPORT Other
"FXPOI, defined as hypergonadotropic hypogonadism before age 40 years, has been observed in 20% of women who carry a premutation allele compared to 1% in the general population"
Supports both the phenotype and the OCCASIONAL frequency band (20% of carriers falls in the HPO 5-29% range).
Secondary amenorrhea HP:0000869 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Secondary amenorrhea (HP:0000869). HP:0000869 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301558 SUPPORT Other
"FXPOI, defined as hypergonadotropic hypogonadism before age 40 years"
The definitional statement implies cessation of menses before age 40. The abstract does not separately describe the secondary-amenorrhea presentation pattern.
Female infertility HP:0008222 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Female infertility (HP:0008222). HP:0008222 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33495935 SUPPORT Human Clinical
"The most frequent conditions associated with POI are Turner syndrome and fragile X pre-mutation"
Places the fragile X premutation among the leading genetic causes of the fertility-limiting POI phenotype. The sentence establishes the causal association rather than quantifying infertility in carriers.
Musculoskeletal 2
Reduced bone mineral density HP:0004349 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Reduced bone mineral density (HP:0004349). HP:0004349 is a phenotype from the Human Phenotype Ontology.
Sequelae: Osteoporosis
Show evidence (1 reference)
PMID:39647506 SUPPORT Human Clinical
"The potential implications include adverse effects on quality of life, on fertility and on bone, cardiovascular and cognitive health."
Identifies bone health as a recognized sequela of POI. The guideline addresses POI as a class and does not quantify bone loss in FXPOI specifically.
Osteoporosis HP:0000939 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Osteoporosis (HP:0000939). HP:0000939 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39647506 SUPPORT Human Clinical
"The potential implications include adverse effects on quality of life, on fertility and on bone, cardiovascular and cognitive health."
Supports bone as a domain of long-term harm in POI. The guideline does not separately quantify established osteoporosis in FXPOI carriers.
Other 4
Elevated serum FSH Elevated circulating follicle stimulating hormone level HP:0008232 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Elevated circulating follicle stimulating hormone level (HP:0008232). HP:0008232 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39647506 SUPPORT INDIRECT Human Clinical
"only one elevated follicle stimulating hormone (FSH) >25 IU is required for diagnosis of POI"
Gives the current diagnostic threshold for the elevated-FSH criterion. Graded INDIRECT because the guideline addresses POI generally, and FXPOI is diagnosed by applying these POI criteria to a premutation carrier.
Oligomenorrhea HP:0000876 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Oligomenorrhea (HP:0000876). HP:0000876 is a phenotype from the Human Phenotype Ontology.
Abnormal anti-Mullerian hormone concentration Abnormal circulating antimullerian hormone concentration HP:0031101 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal circulating antimullerian hormone concentration (HP:0031101). HP:0031101 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39647506 SUPPORT INDIRECT Human Clinical
"guidance that AMH testing, repeat FSH measurement and/or AMH may be required where there is diagnostic uncertainty"
Establishes AMH as a recognized ovarian-reserve measure in POI diagnosis. Graded INDIRECT because the guideline is not FXPOI-specific.
Hot flashes HP:0031217 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hot flashes (HP:0031217). HP:0031217 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39647506 SUPPORT Human Clinical
"The recent update of the POI guideline covers 40 clinical questions on diagnosis of the condition, the different sequelae, including bone, cardiovascular, neurological and sexual function, fertility and general well-being, and treatment options, including HT."
Places symptomatic burden and its treatment with hormone therapy within the POI guideline scope. The snippet does not name vasomotor symptoms specifically; it is the closest verifiable support in the cached literature.
🧬

Genetic Associations

1
FMR1 (A premutation-range CGG repeat expansion (55-200 repeats) in the FMR1 5' UTR at Xq27.3 is the cause of FXPOI. The premutation, not the full mutation, confers the ovarian risk: full-mutation (>200 repeat) alleles are hypermethylated and silenced and cause fragile X syndrome rather than FXPOI. Risk within the premutation range is not monotonic in repeat length. It rises through the low-to-mid range, peaks at roughly 70-100 repeats (highest at 85-89), and then falls away again at the largest premutation sizes, so that carriers below about 65 repeats and above about 120 repeats have no significantly increased risk relative to non-carriers. This inverted-U - the "FXPOI paradox" - is the most distinctive feature of FXPOI genetics and constrains any purely dose-dependent RNA-toxicity model (see discussions).)
Gene: FMR1 hgnc:3775 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is FMR1 (hgnc:3775). hgnc:3775 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (3 references)
PMID:33927378 SUPPORT Human Clinical
"women with 70-100 CGG repeats were at the highest risk for FXPOI using various statistical models to compare average age at menopause and risk of FXPOI, with women with 85-89 repeats being at the highest risk. Importantly, women with <65 repeats or >120 repeats did not have a significantly..."
Large cohort study establishing the non-linear repeat-length risk relationship, including the fall in risk at the largest premutation sizes.
PMID:20301558 SUPPORT Other
"the diagnosis of FXTAS or FXPOI is associated with a premutation-sized repeat (55-200 CGG repeats)"
Establishes FMR1 premutation status as the genetic basis of FXPOI.
PMID:20301558 SUPPORT Other
"FMR1 disorders include fragile X syndrome (FXS), fragile X-associated tremor/ataxia syndrome (FXTAS), and fragile X-associated primary ovarian insufficiency (FXPOI)."
Places FXPOI within the FMR1 disorder spectrum attributable to this gene.
🔬

Variants

1
FMR1 premutation CGG repeat expansion (55-200 repeats) Pathogenic
Gene: FMR1 hgnc:3775 HUGO Gene Nomenclature Committee (hgnc) Relation: this variant is in this gene This variant is in FMR1 (hgnc:3775). hgnc:3775 is a gene from the HUGO Gene Nomenclature Committee. trinucleotide repeat expansion
An unstable CGG trinucleotide repeat expansion of 55-200 units in the FMR1 5' untranslated region. This range is normally spared the CpG-island hypermethylation that silences full-mutation (>200 repeat) alleles, so the premutation allele is transcribed - the basis for its gain-of-function pathogenicity in FXPOI and FXTAS. The allele is unstable on maternal transmission and can expand to a full mutation in offspring, which is the separate fragile X syndrome risk that dominates reproductive counseling for carriers. Two features reported to modify the allele's effect are not curated as evidence-backed claims here because their primary sources could not be fetched in this session: AGG interruptions within the CGG tract, which stabilize the repeat against intergenerational expansion but have not been shown to modify FXPOI risk in the carrier herself; and X-chromosome inactivation skewing, where preferential inactivation of the premutation-bearing allele is reported to be protective.
Show evidence (2 references)
PMID:17618523 SUPPORT Human Clinical
"moderate expansions (55-200 repeats; premutation range) of a CGG trinucleotide in the fragile X mental retardation 1 (FMR1) gene"
Defines the premutation allele class and repeat range.
PMID:28420439 SUPPORT Human Clinical
"more than 99% of individuals have a CGG expansion (>200 triplets) in the 5' UTR of the gene"
Locates the repeat in the FMR1 5' UTR and gives the full-mutation threshold that bounds the premutation range above. The statement describes the full-mutation allele of fragile X syndrome rather than the premutation itself.
💊

Medical Actions

6
Estrogen replacement therapy
Category: Therapeutic Action: sex hormone modifying agent therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is sex hormone modifying agent therapy, annotated with Hormone Therapy (NCIT:C15445). NCIT:C15445 is a clinical intervention from the NCI Thesaurus. Ontology label: Hormone Therapy NCIT:C15445
Agent: 17beta-estradiol CHEBI:16469 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses 17beta-estradiol (CHEBI:16469). CHEBI:16469 is a therapeutic agent from Chemical Entities of Biological Interest. progesterone CHEBI:17026 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses progesterone (CHEBI:17026). CHEBI:17026 is a therapeutic agent from Chemical Entities of Biological Interest.
Systemic estrogen, with a progestogen in women with an intact uterus, is the mainstay of FXPOI management. It relieves vasomotor symptoms and mitigates the bone and cardiovascular consequences of premature estrogen deficiency, and is generally continued to the age of typical natural menopause. It does not restore ovarian function or fertility. Where FXPOI presents before puberty is complete, the same agent is used for pubertal induction before being continued as replacement.
Mechanism Target:
BYPASSES Chronic estrogen deficiency — Exogenous estrogen replaces the missing ovarian hormone output. It acts downstream of the follicle loss and does not correct the repeat-expansion lesion or restore the follicle pool.
Target Phenotypes: Hot flashes HP:0031217 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hot flashes (HP:0031217). HP:0031217 is a phenotype from the Human Phenotype Ontology. Reduced bone mineral density HP:0004349 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Reduced bone mineral density (HP:0004349). HP:0004349 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:20301558 SUPPORT Other
"FXPOI: Gynecologic or reproductive endocrinologic evaluation can provide appropriate treatment and counseling for reproductive considerations and hormone replacement."
GeneReviews names hormone replacement as the FXPOI management approach.
PMID:39647506 SUPPORT Human Clinical
"Although hormone therapy (HT) can mitigate some of these effects, many questions still remain regarding the optimal management of POI."
Supports the mitigating effect of hormone therapy on POI sequelae while recording the residual uncertainty. The guideline addresses POI as a class.
PMID:38677871 SUPPORT INDIRECT Human Clinical
"Pubertal induction and ongoing estrogen replacement therapy are often necessary."
Supports both pubertal induction and continued estrogen replacement in hypergonadotropic POI. Graded INDIRECT because it is written for POI generally.
Fertility preservation counseling and oocyte or embryo cryopreservation
Category: Therapeutic Action: Fertility PreservationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Fertility Preservation (NCIT:C71326). NCIT:C71326 is a clinical intervention from the NCI Thesaurus. NCIT:C71326
Because the timing of follicle depletion is unpredictable and the window closes permanently, women identified as premutation carriers should be counseled about fertility preservation early, while ovarian reserve remains. Oocyte or embryo cryopreservation is the established option once menarche has occurred. Efficacy in premutation carriers may be reduced by the ovarian changes that define the disorder, and ovarian tissue cryopreservation remains experimental in this population.
Show evidence (2 references)
PMID:33495935 SUPPORT Human Clinical
"In case of spontaneous menarche (this can occur variably depending on the mutation) established techniques like embryo or oocyte cryopreservation can be proposed, even if, in some cases, their effectiveness may be reduced by ovarian alterations connected to the mutation."
Supports oocyte and embryo cryopreservation as the established options in genetic POI and records the caveat on reduced effectiveness.
PMID:33495935 SUPPORT Human Clinical
"If a diagnosis is issued before POI onset, counseling on currently available fertility preservation techniques is advisable."
Supports counseling before onset as the intervention window.
Donor oocyte in vitro fertilization
Category: Therapeutic Action: In Vitro FertilizationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is In Vitro Fertilization (NCIT:C16580). NCIT:C16580 is a clinical intervention from the NCI Thesaurus. NCIT:C16580
For carriers who have already progressed to overt ovarian failure and wish to carry a pregnancy, donor oocyte IVF is the standard route, since it does not depend on the woman's own depleted follicle pool. It bypasses both the ovarian phenotype and the risk of transmitting an expanding FMR1 allele. No FXPOI-specific outcome evidence is cited here; this entry records standard practice.
Bone health surveillance and protection
Category: Monitoring Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Because premature estrogen deficiency accelerates bone loss, management includes bone mineral density monitoring alongside calcium and vitamin D sufficiency, with bone-protective pharmacotherapy reserved for established osteoporosis. Hormone therapy is the primary bone-protective measure; this entry covers the surveillance and adjunctive limb.
Show evidence (1 reference)
PMID:39647506 SUPPORT Human Clinical
"The potential implications include adverse effects on quality of life, on fertility and on bone, cardiovascular and cognitive health."
Establishes bone health as a management domain in POI. The guideline addresses POI as a class and this snippet does not specify a surveillance schedule.
Tobacco avoidance
Category: Counseling / Informational Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Avoiding tobacco is specifically recommended in FMR1 premutation carriers because smoking further lowers ovarian reserve and brings forward the onset of FXPOI. It is the one modifiable exposure GeneReviews lists for FXPOI.
Show evidence (1 reference)
PMID:20301558 SUPPORT Other
"FXPOI: tobacco use as this decreases ovarian reserve and the age of onset of FXPOI."
GeneReviews lists tobacco under agents/circumstances to avoid for FXPOI, making avoidance the corresponding management action.
Genetic counseling and reproductive genetic testing
Category: Counseling / Informational Action: genetic counselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is genetic counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. Ontology label: Genetic Counseling NCIT:C15240
Counseling covers two distinct risks that must not be conflated: the woman's own risk of FXPOI and FXTAS, and the risk of transmitting an allele that expands to a full mutation and causes fragile X syndrome in offspring. Cascade testing of at-risk female relatives is standard, and prenatal or preimplantation genetic testing is available once the family allele is known.
Show evidence (2 references)
PMID:20301558 SUPPORT Other
"Mothers and their female relatives who are heterozygous for a premutation are at increased risk for FXTAS, FXPOI, and fragile X-associated neuropsychiatric disorders (FXAND)"
Supports cascade testing of at-risk female relatives and the carrier's own risk counseling.
PMID:20301558 SUPPORT Other
"Prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible once an expanded (or altered) FMR1 allele has been identified in a family member."
Supports the reproductive genetic testing options offered to carriers.
🌍

Environmental Factors

1
Tobacco use
tobacco use ECTO:6000029 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is tobacco use, annotated with exposure to tobacco smoking (ECTO:6000029). ECTO:6000029 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Tobacco use is an avoidable exposure in FMR1 premutation carriers because it lowers ovarian reserve and brings forward the age of onset of FXPOI. It is not a cause of FXPOI; it modifies the timing of a genetically determined process.
Show evidence (1 reference)
PMID:20301558 SUPPORT Other
"FXPOI: tobacco use as this decreases ovarian reserve and the age of onset of FXPOI."
GeneReviews lists tobacco under agents/circumstances to avoid for FXPOI, with the stated mechanism of reduced ovarian reserve and earlier onset.
🔬

Biochemical Markers

2
Serum follicle stimulating hormone
Show evidence (1 reference)
PMID:39647506 SUPPORT Human Clinical
"only one elevated follicle stimulating hormone (FSH) >25 IU is required for diagnosis of POI"
Specifies the diagnostic threshold used for this biochemical marker. The threshold is defined for POI as a class.
Serum anti-Mullerian hormone
Show evidence (1 reference)
PMID:39647506 SUPPORT INDIRECT Human Clinical
"Questions were added on the role of anti-Müllerian hormone (AMH) in the diagnosis of POI"
Documents the formal role of AMH in current POI diagnostic guidance. Graded INDIRECT because the guideline is not FXPOI-specific.
🔬

Diagnosis

3
FMR1 CGG repeat sizing
Targeted molecular testing for the FMR1 CGG repeat (PCR-based repeat sizing with Southern blot as needed) is the definitive test. Standard multigene panels and exome or genome sequencing do not reliably detect the repeat expansion, so FMR1 testing must be ordered specifically. FMR1 testing is a standard component of the POI diagnostic workup.
Show evidence (2 references)
PMID:20301558 SUPPORT Other
"The diagnosis of an FMR1 disorder is established through the use of specialized molecular genetic testing to detect CGG trinucleotide repeat expansion in the 5' UTR of FMR1"
Identifies the specialized repeat-sizing assay as the diagnostic test.
PMID:20301558 SUPPORT Other
"typical multigene panels and comprehensive genomic testing (exome or genome sequencing) are useful only when no CGG repeat expansion is detected"
Supports the caution that routine sequencing does not substitute for dedicated repeat sizing.
Ovarian reserve assessment
Serum AMH and antral follicle count on pelvic ultrasound, together with serum FSH and estradiol, index ovarian reserve and can detect the occult phase before amenorrhea. Serial rather than single measurements are informative because ovarian activity in FXPOI can fluctuate.
Show evidence (1 reference)
PMID:39647506 SUPPORT INDIRECT Human Clinical
"guidance that AMH testing, repeat FSH measurement and/or AMH may be required where there is diagnostic uncertainty"
Supports serial FSH and AMH testing in the diagnostic workup. Graded INDIRECT because the guideline covers POI generally and does not separately address antral follicle count.
Karyotype and autoimmune workup
Karyotype and adrenal/ovarian autoantibody testing are performed alongside FMR1 repeat sizing to exclude Turner syndrome, other X-chromosome abnormalities, and autoimmune oophoritis in a woman presenting with POI. These are exclusionary rather than confirmatory for FXPOI.
📊

Prevalence

1
Female FMR1 premutation carriers
Lifetime Prevalence 20000.0 per 100,000 Common
Approximately 20% of female FMR1 premutation carriers develop FXPOI, versus about 1% background POI prevalence. This is a within-carrier penetrance figure, not a population prevalence, and it derives largely from cohorts ascertained through fragile X families, which may overstate absolute risk among carriers identified by unselected population screening.
Show evidence (1 reference)
PMID:20301558 SUPPORT Other
"FXPOI, defined as hypergonadotropic hypogonadism before age 40 years, has been observed in 20% of women who carry a premutation allele compared to 1% in the general population"
Source of both the carrier-level figure and the general-population comparator.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Fragile X-Associated Primary Ovarian Insufficiency:

Primary ovarian insufficiency of other cause
Overlapping Features POI from any other cause presents with the same hypergonadotropic endocrine picture. Turner syndrome and other X-chromosome abnormalities, autoimmune oophoritis, iatrogenic causes (gonadotoxic chemotherapy, pelvic radiation, oophorectomy), and other monogenic POI genes are the main alternatives, which is why karyotype, autoantibody testing, and FMR1 repeat sizing are run together in the POI workup.
Distinguishing Features
  • Absence of an FMR1 premutation on dedicated CGG repeat sizing.
  • Turner syndrome and other X-chromosome abnormalities are identified by karyotype.
Show evidence (1 reference)
PMID:33495935 SUPPORT Human Clinical
"About 10% of cases of POI is related to genetic diseases. The most frequent conditions associated with POI are Turner syndrome and fragile X pre-mutation"
Identifies Turner syndrome as the principal competing genetic diagnosis alongside the fragile X premutation.
Fragile X syndrome MONDO:0010383
Overlapping Features The full-mutation FMR1 disorder. It is caused by the same locus but by a different allele class and a mechanistically opposite lesion - hypermethylation and silencing with loss of FMRP, rather than transcription of a toxic expanded-repeat mRNA - and it does not carry the FXPOI ovarian phenotype.
Distinguishing Features
  • Repeat size greater than 200 CGG with abnormal methylation rather than 55-200 unmethylated repeats.
  • Neurodevelopmental presentation with intellectual disability rather than an ovarian phenotype.
Show evidence (1 reference)
PMID:20301558 SUPPORT Other
"a definite diagnosis of FXS requires the presence of a full-mutation repeat size (>200 CGG repeats) while the diagnosis of FXTAS or FXPOI is associated with a premutation-sized repeat (55-200 CGG repeats)"
States the allele-class distinction between fragile X syndrome and FXPOI.
Fragile X-associated tremor/ataxia syndrome MONDO:0010382
Overlapping Features The other premutation disorder. It shares the FMR1 premutation genotype and the RNA gain-of-function paradigm with FXPOI but affects the nervous system, presents in the seventh decade, and occurs in male as well as female carriers. FXTAS is a co-occurring risk in the same women rather than a competing explanation for their amenorrhea.
Distinguishing Features
  • Late-onset progressive cerebellar ataxia and intention tremor rather than an ovarian phenotype.
  • Affects hemizygous male carriers, in whom FXPOI cannot occur.
Show evidence (1 reference)
PMID:20301558 SUPPORT Other
"FXTAS occurs in individuals who have an FMR1 premutation and is characterized by late-onset, progressive cerebellar ataxia and intention tremor followed by cognitive impairment."
Distinguishes the neurological premutation phenotype from the ovarian one on onset age, organ system, and affected sex.
{ }

Source YAML

click to show 
name: Fragile X-Associated Primary Ovarian Insufficiency
creation_date: "2026-07-31T00:00:00Z"
category: Mendelian
parents:
- Trinucleotide Repeat Disorder
- Primary Ovarian Insufficiency
description: >-
  Fragile X-associated primary ovarian insufficiency (FXPOI; OMIM premature ovarian
  failure 1, POF1) is the ovarian disorder of FMR1 premutation carriers (55-200 CGG
  repeats in the FMR1 5' UTR). It is one of the three recognized FMR1 disorders,
  alongside full-mutation fragile X syndrome (FXS) and the premutation neurodegenerative
  disorder FXTAS. FXPOI is defined as hypergonadotropic hypogonadism before age 40 and
  is observed in about 20% of female premutation carriers, compared with about 1% of
  the general population; a larger fraction show subclinical ("occult") ovarian
  insufficiency with declining ovarian reserve before FSH crosses the diagnostic
  threshold. Like FXTAS, and unlike FXS, FXPOI is a premutation phenotype: the expanded
  allele largely escapes methylation-mediated silencing and is transcribed at elevated
  levels, so pathogenesis is attributed to a toxic gain-of-function of the expanded
  CGG-repeat FMR1 mRNA, with a proposed parallel contribution from repeat-associated
  non-AUG (RAN) translation of the polyglycine protein FMRpolyG, rather than to loss of
  FMRP. Ovarian consequences are granulosa cell dysfunction and accelerated depletion of
  the follicle pool, giving menstrual irregularity, subfertility, early menopause, and
  the long-term sequelae of premature estrogen deficiency (bone loss, cardiovascular
  risk, vasomotor symptoms, psychosocial burden). Because intermittent ovulatory
  function can persist after diagnosis, FXPOI is described as an insufficiency rather
  than an absolute failure.
synonyms:
- FXPOI
- premature ovarian failure 1
- POF1
- FMR1-related primary ovarian insufficiency
- fragile X-associated premature ovarian failure
disease_term:
  preferred_term: Fragile X-Associated Primary Ovarian Insufficiency
  term:
    id: MONDO:0010706
    label: premature ovarian failure 1
references:
- reference: PMID:20301558
  title: "FMR1 Disorders."
  tags:
  - GeneReviews
classifications:
  harrisons_chapter:
  - classification_value: ENDOCRINOLOGY_METABOLISM
    notes: >-
      FXPOI presents and is managed as hypergonadotropic hypogonadism - a reproductive
      endocrine disorder - which is where its diagnosis (FSH, AMH) and treatment (hormone
      therapy, fertility preservation) sit clinically.
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    notes: >-
      Its cause is a Mendelian, X-linked FMR1 repeat expansion, and the practical entry
      point for most carriers is genetic testing and cascade counseling rather than an
      endocrine presentation.
inheritance:
- name: X-linked inheritance
  inheritance_term:
    preferred_term: X-linked inheritance
    term:
      id: HP:0001417
      label: X-linked inheritance
  penetrance: INCOMPLETE
  expressivity: VARIABLE
  description: >-
    FXPOI is transmitted in an X-linked manner via FMR1 premutation alleles. Penetrance
    is incomplete: roughly 20% of heterozygous female premutation carriers develop
    hypergonadotropic hypogonadism before age 40, and expressivity ranges from
    subclinical diminished ovarian reserve to overt amenorrhea. Male premutation
    carriers do not manifest FXPOI but transmit the premutation to all of their
    daughters, who are then at risk.
  evidence:
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FMR1 disorders are inherited in an X-linked manner."
    explanation: GeneReviews establishes X-linked inheritance for the FMR1 disorders, including FXPOI.
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Males with FXTAS will transmit their FMR1 premutation expansion to all of their daughters, who will be heterozygous for a premutation and at increased risk for FXTAS, FXPOI, and FXAND."
    explanation: >-
      Documents the X-linked transmission pattern specific to FXPOI risk, including the
      obligate transmission from premutation-carrier fathers to all daughters.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_fmr1_premutation_ovarian_rna_gof_model
  hypothesis_label: Canonical FMR1 Premutation RNA Gain-of-Function (± RAN-Translation) Model of Ovarian Toxicity
  status: CANONICAL
  description: >-
    FXPOI is attributed to the same premutation gain-of-function paradigm established for
    FXTAS, applied to the ovary. The 55-200 CGG premutation allele largely escapes the
    hypermethylation that silences the full mutation, is transcribed at elevated levels,
    and the expanded CGG-repeat FMR1 mRNA is itself toxic - forming nuclear RNA foci that
    sequester CGG-repeat-binding proteins away from their normal functions. A parallel,
    non-exclusive arm is repeat-associated non-AUG (RAN) translation of the expanded
    repeat into an aggregation-prone polyglycine protein, FMRpolyG. In the ovary these
    converge on granulosa cell dysfunction and death and on accelerated depletion of the
    follicle pool, producing hypergonadotropic hypogonadism before age 40. Note the
    directional contrast with FXS, where >200 repeats silence FMR1 and disease arises
    from loss of FMRP: FXPOI is not an FMRP-deficiency phenotype.
  evidence:
  - reference: PMID:17618523
    reference_title: "Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "The pathogenic mechanism is related to overexpression and toxicity of the FMR1 mRNA per se."
    explanation: >-
      Establishes the FMR1 mRNA toxic gain-of-function paradigm for premutation disease.
      Graded INDIRECT because this statement is made for FXTAS; its extension to the
      ovarian phenotype is an inference from the shared premutation genotype rather than
      a direct ovarian observation in this paper.
  - reference: PMID:25954027
    reference_title: RAN translation at CGG repeats induces ubiquitin proteasome system impairment in models of fragile X-associated tremor ataxia syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "the repeat also elicits production of a toxic polyglycine protein, FMRpolyG, via repeat-associated non-AUG (RAN)-initiated translation"
    explanation: >-
      Supplies the RAN-translation/FMRpolyG arm of the premutation gain-of-function
      model. The experiments are Drosophila and transfected-cell models of FXTAS, not
      ovarian tissue.
pathophysiology:
- name: FMR1 premutation CGG expansion and elevated FMR1 mRNA
  description: >-
    The initiating lesion is a premutation-range (55-200 CGG) trinucleotide repeat
    expansion in the FMR1 5' UTR at Xq27.3. Unlike the full mutation (>200 repeats),
    which is hypermethylated and transcriptionally silenced, the premutation allele
    remains largely unmethylated and is actively transcribed, producing elevated levels
    of an FMR1 mRNA carrying the expanded CGG tract. This transcript, not the loss of
    FMRP, is the proximate pathogenic species.
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  gene:
    preferred_term: FMR1
    modifier: INCREASED
    term:
      id: hgnc:3775
      label: FMR1
  biological_processes:
  - preferred_term: gene expression
    term:
      id: GO:0010467
      label: gene expression
    modifier: INCREASED
  locations:
  - preferred_term: ovary
    term:
      id: UBERON:0000992
      label: ovary
  evidence:
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the diagnosis of FXTAS or FXPOI is associated with a premutation-sized repeat (55-200 CGG repeats)"
    explanation: GeneReviews anchors FXPOI to the premutation repeat range rather than the full mutation.
  - reference: PMID:17618523
    reference_title: "Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "moderate expansions (55-200 repeats; premutation range) of a CGG trinucleotide in the fragile X mental retardation 1 (FMR1) gene, the same gene which causes fragile X syndrome when in the full mutation range (200 or greater CGG repeats)"
    explanation: >-
      Defines the premutation repeat range and its contrast with the full mutation at the
      same locus, the genetic basis of this node.
  downstream:
  - target: RNA gain-of-function and sequestration of CGG-repeat-binding proteins
    causal_link_type: DIRECT
    description: >-
      The elevated expanded-repeat transcript forms the nuclear RNA species that binds and
      sequesters CGG-repeat-binding proteins.
    evidence:
    - reference: PMID:17618523
      reference_title: "Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The pathogenic mechanism is related to overexpression and toxicity of the FMR1 mRNA per se."
      explanation: >-
        Links elevated expanded-repeat FMR1 mRNA to toxicity, the step this edge
        asserts. The statement is made for the neurological premutation phenotype.
  - target: RAN translation and FMRpolyG production
    causal_link_type: DIRECT
    description: >-
      The same expanded CGG tract in the transcript is the substrate for
      repeat-associated non-AUG translation.
- name: RNA gain-of-function and sequestration of CGG-repeat-binding proteins
  description: >-
    The expanded CGG-repeat FMR1 mRNA forms nuclear RNA aggregates that bind and sequester
    CGG-repeat-binding proteins - identified in FXTAS models as Pur alpha and hnRNP A2/B1 -
    depleting them from their normal functions. This is the leading arm of premutation
    toxicity. The direct ovarian evidence is thinner than the neuronal evidence from FXTAS
    models; its application to granulosa cells is an extension of the shared premutation
    mechanism rather than a directly demonstrated ovarian finding.
  biological_scale: MOLECULAR
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:17698009
    reference_title: Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "transcribed premutation repeats alone are sufficient to cause neurodegeneration, suggesting that rCGG-repeat-binding proteins (RBPs) may be sequestered from their normal function by rCGG binding"
    explanation: >-
      Provides the mechanistic basis for RNA-mediated protein sequestration by
      premutation transcripts. The model is Drosophila neurons, not ovarian tissue.
  - reference: PMID:25954027
    reference_title: RAN translation at CGG repeats induces ubiquitin proteasome system impairment in models of fragile X-associated tremor ataxia syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "FXTAS is thought to arise primarily from an RNA gain-of-function toxicity mechanism."
    explanation: >-
      States the primacy of the RNA gain-of-function route among premutation mechanisms.
      The claim is framed for FXTAS.
  - reference: PMID:36250920
    reference_title: "Evidence for a fragile X messenger ribonucleoprotein 1 (FMR1) mRNA gain-of-function toxicity mechanism contributing to the pathogenesis of fragile X-associated premature ovarian insufficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "identified proteins that are specifically sequestered by CGG RNA aggregates in granulosa cells in vitro"
    explanation: >-
      Shows the sequestration step asserted by this node occurring in granulosa cells
      specifically, rather than only in the neuronal FXTAS models. The node is nonetheless
      held at PROVISIONAL because which sequestered protein is functionally decisive for
      the follicle remains open.
  downstream:
  - target: Granulosa cell dysfunction and death
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Sequestration of RNA-binding proteins is proposed to impair the somatic support cells
      of the follicle, but the intermediate steps are not established in the human ovary.
- name: RAN translation and FMRpolyG production
  description: >-
    Repeat-associated non-AUG (RAN) translation initiates within the expanded CGG tract and
    produces an aggregation-prone polyglycine protein, FMRpolyG. This is the parallel
    protein-toxicity arm of the premutation mechanism, and the evidence that it is
    initiated at all comes from FXTAS models rather than ovarian tissue. Its standing in
    the ovary is now constrained rather than simply open: in the granulosa cell model,
    expanded CGG-repeat RNA causes cell death independently of FMRpolyG, so the RNA arm is
    sufficient for the granulosa lesion and FMRpolyG is not required for it. What remains
    unresolved is whether FMRpolyG makes any additional contribution to FXPOI on top of
    the RNA arm - not whether the RNA arm needs it.
  biological_scale: MOLECULAR
  mechanism_confidence: PROVISIONAL
  biological_processes:
  - preferred_term: regulation of translation
    term:
      id: GO:0006417
      label: regulation of translation
    modifier: ABNORMAL
  evidence:
  - reference: PMID:25954027
    reference_title: RAN translation at CGG repeats induces ubiquitin proteasome system impairment in models of fragile X-associated tremor ataxia syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "the repeat also elicits production of a toxic polyglycine protein, FMRpolyG, via repeat-associated non-AUG (RAN)-initiated translation"
    explanation: >-
      Establishes RAN translation of FMRpolyG from the expanded CGG repeat. The models
      are Drosophila and transfected mammalian cells studied for FXTAS.
  downstream:
  - target: Granulosa cell dysfunction and death
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      FMRpolyG may contribute to granulosa cell injury, but it is demonstrably not required
      for it: granulosa cell death occurs independently of FMRpolyG expression. This edge
      is therefore retained as a possible additive contribution, not a necessary step.
    evidence:
    - reference: PMID:36250920
      reference_title: "Evidence for a fragile X messenger ribonucleoprotein 1 (FMR1) mRNA gain-of-function toxicity mechanism contributing to the pathogenesis of fragile X-associated premature ovarian insufficiency."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "these aggregates were able to cause significant granulosa cell death independent of FMRpolyG expression"
      explanation: >-
        It constrains the edge rather than establishing it: the granulosa lesion does
        not require FMRpolyG, so any additive FMRpolyG contribution is untested.
- name: Granulosa cell dysfunction and death
  description: >-
    The cellular lesion is in the granulosa cells that support the developing follicle:
    dysregulated folliculogenesis signaling (including altered AMH output) and granulosa
    cell death. Granulosa cells, not oocytes, are the cell type in which premutation
    toxicity has been most directly implicated. The node is held at PROVISIONAL rather than
    ESTABLISHED because its support, while genuinely ovarian, comes entirely from an
    ectopic-expression granulosa cell model plus premutation mice - there is no observation
    in granulosa cells from premutation carriers themselves. The attached KNOWLEDGE_GAP
    discussion records what would close that.
  biological_scale: CELLULAR
  mechanism_confidence: PROVISIONAL
  cell_types:
  - preferred_term: granulosa cell
    term:
      id: CL:0000501
      label: granulosa cell
  biological_processes:
  - preferred_term: apoptotic process
    term:
      id: GO:0006915
      label: apoptotic process
    modifier: INCREASED
  locations:
  - preferred_term: ovary
    term:
      id: UBERON:0000992
      label: ovary
  evidence:
  - reference: PMID:36250920
    reference_title: "Evidence for a fragile X messenger ribonucleoprotein 1 (FMR1) mRNA gain-of-function toxicity mechanism contributing to the pathogenesis of fragile X-associated premature ovarian insufficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "we have developed an in vitro granulosa cell model of the FMR1 premutation by ectopically expressing CGG-repeat RNA and FMRpolyG protein. We show that expanded CGG-repeat RNA accumulated in intranuclear RNA structures, and these aggregates were able to cause significant granulosa cell death independent of FMRpolyG expression."
    explanation: >-
      Direct ovarian-cell evidence that expanded CGG-repeat RNA kills granulosa cells, and
      that it does so independently of FMRpolyG - establishing the RNA arm as sufficient
      for the granulosa lesion.
  - reference: PMID:36250920
    reference_title: "Evidence for a fragile X messenger ribonucleoprotein 1 (FMR1) mRNA gain-of-function toxicity mechanism contributing to the pathogenesis of fragile X-associated premature ovarian insufficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "reduced expression of three proteins ... FUS, PA2G4 and TRA2β ... in ovarian follicles in a FMR1 premutation mouse model"
    explanation: >-
      Extends the sequestration finding from cultured granulosa cells into ovarian follicles
      in vivo, naming the depleted RNA-binding proteins.
  - reference: PMID:22470123
    reference_title: Ovarian abnormalities in a mouse model of fragile X primary ovarian insufficiency.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "PM follicles are smaller and have fewer granulosa cells (GCs) than normal."
    explanation: >-
      Independent in vivo confirmation that the granulosa compartment is depleted in
      premutation ovaries.
  downstream:
  - target: Accelerated ovarian follicle depletion
    causal_link_type: DIRECT
    description: >-
      Loss of granulosa cell support accelerates the attrition of follicles from the
      ovarian reserve.
- name: Accelerated ovarian follicle depletion
  description: >-
    The tissue-level consequence is faster-than-normal attrition of the ovarian follicle
    pool. The reserve is established normally and puberty proceeds normally; it is the
    subsequent rate of loss that is abnormal, which is why FXPOI presents as premature
    reproductive aging rather than as a congenital gonadal dysgenesis. An additional
    mechanism proposed from Fmr1 mouse work - premature mTOR-driven recruitment of
    primordial follicles, i.e. accelerated burn-through of the reserve rather than
    increased death alone - is noted here but not asserted as an evidence-backed node
    (see notes).
  biological_scale: TISSUE
  mechanism_confidence: ESTABLISHED
  cell_types:
  - preferred_term: oocyte
    term:
      id: CL:0000023
      label: oocyte
  biological_processes:
  - preferred_term: ovarian follicle development
    term:
      id: GO:0001541
      label: ovarian follicle development
    modifier: ABNORMAL
  locations:
  - preferred_term: ovary
    term:
      id: UBERON:0000992
      label: ovary
  evidence:
  - reference: PMID:22470123
    reference_title: Ovarian abnormalities in a mouse model of fragile X primary ovarian insufficiency.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the gross development of the ovary and the establishment of the primordial follicle pool is normal in these mice. However, these animals show a faster loss of follicles of all follicle classes, suggesting that the problem is intrinsic to the ovary."
    explanation: >-
      Directly supports this node's specific claim - that the reserve is established
      normally and it is the subsequent attrition rate that is abnormal - and localizes the
      lesion to the ovary itself rather than to central endocrine control.
  downstream:
  - target: Hypergonadotropic hypogonadism
    causal_link_type: DIRECT
    description: >-
      Loss of the follicle pool removes the ovarian source of estradiol and of the
      inhibin/AMH feedback signals to the pituitary.
    evidence:
    - reference: PMID:38677871
      reference_title: Primary Amenorrhea and Premature Ovarian Insufficiency.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "primary/premature ovarian insufficiency due to hypergonadotropic hypogonadism"
      explanation: >-
        Ties loss of ovarian function to the hypergonadotropic endocrine state this edge
        produces. The review covers POI as a class.
- name: Hypergonadotropic hypogonadism
  description: >-
    Depletion of the follicle pool removes ovarian estradiol and inhibin output, releasing
    the pituitary from negative feedback and producing menopausal-range FSH with low
    estradiol before age 40 - the defining endocrine state of FXPOI. Ovarian function is
    not always absolutely lost: intermittent ovulatory activity may persist, so
    spontaneous conception after diagnosis is unlikely but not impossible.
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  evidence:
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FXPOI, defined as hypergonadotropic hypogonadism before age 40 years, has been observed in 20% of women who carry a premutation allele compared to 1% in the general population"
    explanation: >-
      GeneReviews defines FXPOI by this endocrine state and quantifies its excess over the
      general population.
  - reference: PMID:38677871
    reference_title: Primary Amenorrhea and Premature Ovarian Insufficiency.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "This review focuses on primary amenorrhea and primary/premature ovarian insufficiency due to hypergonadotropic hypogonadism."
    explanation: >-
      Confirms hypergonadotropic hypogonadism as the endocrine mechanism of premature
      ovarian insufficiency generally. Graded INDIRECT because the review is about POI
      as a class, not FXPOI specifically.
  downstream:
  - target: Chronic estrogen deficiency
    causal_link_type: DIRECT
    description: >-
      Sustained hypoestrogenism from an age decades before typical menopause drives the
      long-term morbidity of FXPOI.
    evidence:
    - reference: PMID:39647506
      reference_title: "Evidence-based guideline: premature ovarian insufficiency(†)(‡)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The potential implications include adverse effects on quality of life, on fertility and on bone, cardiovascular and cognitive health."
      explanation: >-
        Enumerates the downstream morbidity this edge asserts follows loss of ovarian
        hormone output. The guideline addresses POI as a class.
- name: Chronic estrogen deficiency
  description: >-
    Premature and prolonged estrogen deficiency is the source of the non-reproductive
    morbidity of FXPOI: vasomotor symptoms, accelerated bone loss with reduced bone
    mineral density, adverse cardiovascular risk, and effects on quality of life. This is
    the rationale for hormone therapy continued to the age of typical natural menopause,
    and it is shared with primary ovarian insufficiency of any cause rather than being
    specific to the FMR1 premutation.
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  evidence:
  - reference: PMID:39647506
    reference_title: "Evidence-based guideline: premature ovarian insufficiency(†)(‡)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The potential implications include adverse effects on quality of life, on fertility and on bone, cardiovascular and cognitive health. Although hormone therapy (HT) can mitigate some of these effects, many questions still remain regarding the optimal management of POI."
    explanation: >-
      The 2024 international POI guideline enumerates the sequelae of premature estrogen
      deficiency and the mitigating role of hormone therapy. It addresses POI as a class
      rather than the FMR1 premutation subtype.
  downstream:
  - target: Estrogen-deficiency bone remodeling imbalance
    causal_link_type: DIRECT
    description: >-
      Loss of estrogen uncouples bone resorption from formation, the entry point of the
      conserved osteoporosis mechanism.
- name: Estrogen-deficiency bone remodeling imbalance
  description: >-
    Premature loss of ovarian estrogen uncouples osteoclastic resorption from osteoblastic
    formation, which is the initiating lesion of the conserved osteoporosis mechanism. The
    downstream chain (RANKL-driven osteoclastogenesis, increased resorption, net bone loss)
    is not duplicated here; this node declares conformance to the shared module instead.
    The driver is hormonal, which is precisely the case the module's trigger node is
    written to accommodate.
  biological_scale: TISSUE
  mechanism_confidence: ESTABLISHED
  conforms_to: "osteoporosis_bone_resorption#Bone Remodeling Imbalance"
  evidence:
  - reference: PMID:39647506
    reference_title: "Evidence-based guideline: premature ovarian insufficiency(†)(‡)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The potential implications include adverse effects on quality of life, on fertility and on bone, cardiovascular and cognitive health."
    explanation: >-
      Establishes bone as an affected system in POI. The guideline states the clinical
      consequence rather than the remodeling-imbalance mechanism, which is carried by
      the conformance to the osteoporosis module.
phenotypes:
- category: Reproductive
  name: Premature ovarian insufficiency
  description: >-
    Hypergonadotropic hypogonadism before age 40, the defining phenotype of FXPOI,
    observed in approximately 20% of female FMR1 premutation carriers versus about 1% of
    the general female population.
  phenotype_term:
    preferred_term: Premature ovarian insufficiency
    term:
      id: HP:0008209
      label: Premature ovarian insufficiency
  frequency: OCCASIONAL
  diagnostic: true
  evidence:
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FXPOI, defined as hypergonadotropic hypogonadism before age 40 years, has been observed in 20% of women who carry a premutation allele compared to 1% in the general population"
    explanation: >-
      Supports both the phenotype and the OCCASIONAL frequency band (20% of carriers falls
      in the HPO 5-29% range).
- category: Endocrine
  name: Hypergonadotropic hypogonadism
  description: >-
    Elevated gonadotropins with low estradiol resulting from loss of ovarian follicular
    feedback; the endocrine signature that distinguishes FXPOI from central
    (hypothalamic-pituitary) causes of amenorrhea.
  phenotype_term:
    preferred_term: Hypergonadotropic hypogonadism
    term:
      id: HP:0000815
      label: Hypergonadotropic hypogonadism
  diagnostic: true
  evidence:
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FXPOI, defined as hypergonadotropic hypogonadism before age 40 years"
    explanation: GeneReviews makes hypergonadotropic hypogonadism definitional for FXPOI.
- category: Laboratory
  name: Elevated serum FSH
  description: >-
    Menopausal-range follicle stimulating hormone is the key laboratory criterion for
    primary ovarian insufficiency; current international guidance requires a single FSH
    above 25 IU/L, a change from earlier two-sample criteria.
  phenotype_term:
    preferred_term: Elevated circulating follicle stimulating hormone level
    term:
      id: HP:0008232
      label: Elevated circulating follicle stimulating hormone level
  diagnostic: true
  evidence:
  - reference: PMID:39647506
    reference_title: "Evidence-based guideline: premature ovarian insufficiency(†)(‡)."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "only one elevated follicle stimulating hormone (FSH) >25 IU is required for diagnosis of POI"
    explanation: >-
      Gives the current diagnostic threshold for the elevated-FSH criterion. Graded
      INDIRECT because the guideline addresses POI generally, and FXPOI is diagnosed by
      applying these POI criteria to a premutation carrier.
- category: Reproductive
  name: Secondary amenorrhea
  description: >-
    Cessation of previously established menses before age 40. Onset may be abrupt and
    permanent or preceded by years of fluctuating cycles.
  phenotype_term:
    preferred_term: Secondary amenorrhea
    term:
      id: HP:0000869
      label: Secondary amenorrhea
  evidence:
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FXPOI, defined as hypergonadotropic hypogonadism before age 40 years"
    explanation: >-
      The definitional statement implies cessation of menses before age 40. The abstract
      does not separately describe the secondary-amenorrhea presentation pattern.
- category: Reproductive
  name: Delayed puberty
  description: >-
    In the small minority of carriers whose ovarian insufficiency begins before puberty is
    complete, FXPOI presents as delayed puberty and primary rather than secondary
    amenorrhea, and pubertal induction rather than replacement is the initial management
    need. This is the rare end of the onset spectrum, not the typical presentation.
  phenotype_term:
    preferred_term: Delayed puberty
    term:
      id: HP:0000823
      label: Delayed puberty
  evidence:
  - reference: PMID:38677871
    reference_title: Primary Amenorrhea and Premature Ovarian Insufficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pubertal induction and ongoing estrogen replacement therapy are often necessary."
    explanation: >-
      Establishes that hypergonadotropic ovarian insufficiency can present before
      puberty is complete and require pubertal induction. The review covers POI as a
      class and does not quantify this presentation in FMR1 premutation carriers.
- category: Reproductive
  name: Oligomenorrhea
  description: >-
    Infrequent or irregular menstrual cycles, frequently the earliest clinical
    manifestation and often preceding overt amenorrhea by months to years.
  phenotype_term:
    preferred_term: Oligomenorrhea
    term:
      id: HP:0000876
      label: Oligomenorrhea
- category: Reproductive
  name: Female infertility
  description: >-
    Subfertility and infertility from diminished and then absent ovarian reserve.
    Intermittent ovarian activity means that conception, while unlikely, remains possible
    for some women after diagnosis - a point that distinguishes FXPOI counseling from
    post-menopausal counseling.
  phenotype_term:
    preferred_term: Female infertility
    term:
      id: HP:0008222
      label: Female infertility
  evidence:
  - reference: PMID:33495935
    reference_title: Fertility preservation for genetic diseases leading to premature ovarian insufficiency (POI).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most frequent conditions associated with POI are Turner syndrome and fragile X pre-mutation"
    explanation: >-
      Places the fragile X premutation among the leading genetic causes of the
      fertility-limiting POI phenotype. The sentence establishes the causal association
      rather than quantifying infertility in carriers.
- category: Laboratory
  name: Abnormal anti-Mullerian hormone concentration
  description: >-
    Reduced anti-Mullerian hormone reflects diminished ovarian reserve and can fall before
    FSH rises, making it useful for detecting the occult phase of FXPOI. AMH has been
    formally incorporated into POI diagnostic guidance where there is diagnostic
    uncertainty.
  phenotype_term:
    preferred_term: Abnormal circulating antimullerian hormone concentration
    term:
      id: HP:0031101
      label: Abnormal circulating antimullerian hormone concentration
  evidence:
  - reference: PMID:39647506
    reference_title: "Evidence-based guideline: premature ovarian insufficiency(†)(‡)."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "guidance that AMH testing, repeat FSH measurement and/or AMH may be required where there is diagnostic uncertainty"
    explanation: >-
      Establishes AMH as a recognized ovarian-reserve measure in POI diagnosis. Graded
      INDIRECT because the guideline is not FXPOI-specific.
- category: Constitutional
  name: Hot flashes
  description: >-
    Vasomotor symptoms arising from premature hypoestrogenism, and one of the symptom
    domains hormone therapy is given to relieve.
  phenotype_term:
    preferred_term: Hot flashes
    term:
      id: HP:0031217
      label: Hot flashes
  evidence:
  - reference: PMID:39647506
    reference_title: "Evidence-based guideline: premature ovarian insufficiency(†)(‡)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The recent update of the POI guideline covers 40 clinical questions on diagnosis of the condition, the different sequelae, including bone, cardiovascular, neurological and sexual function, fertility and general well-being, and treatment options, including HT."
    explanation: >-
      Places symptomatic burden and its treatment with hormone therapy within the POI
      guideline scope. The snippet does not name vasomotor symptoms specifically; it is
      the closest verifiable support in the cached literature.
- category: Skeletal
  name: Reduced bone mineral density
  description: >-
    Accelerated bone loss follows premature estrogen deficiency and is one of the
    principal long-term morbidities requiring proactive management; untreated, it
    progresses toward osteoporosis. This is a downstream consequence of hypoestrogenism
    rather than a direct effect of the FMR1 premutation on bone.
  phenotype_term:
    preferred_term: Reduced bone mineral density
    term:
      id: HP:0004349
      label: Reduced bone mineral density
  sequelae:
  - target: Osteoporosis
    causal_link_type: DIRECT
    description: >-
      Sustained bone loss from untreated premature estrogen deficiency progresses to
      established osteoporosis.
  evidence:
  - reference: PMID:39647506
    reference_title: "Evidence-based guideline: premature ovarian insufficiency(†)(‡)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The potential implications include adverse effects on quality of life, on fertility and on bone, cardiovascular and cognitive health."
    explanation: >-
      Identifies bone health as a recognized sequela of POI. The guideline addresses POI
      as a class and does not quantify bone loss in FXPOI specifically.
- category: Skeletal
  name: Osteoporosis
  description: >-
    Established osteoporosis is the end point of untreated premature estrogen deficiency
    and is a target of bone-protective management.
  phenotype_term:
    preferred_term: Osteoporosis
    term:
      id: HP:0000939
      label: Osteoporosis
  evidence:
  - reference: PMID:39647506
    reference_title: "Evidence-based guideline: premature ovarian insufficiency(†)(‡)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The potential implications include adverse effects on quality of life, on fertility and on bone, cardiovascular and cognitive health."
    explanation: >-
      Supports bone as a domain of long-term harm in POI. The guideline does not
      separately quantify established osteoporosis in FXPOI carriers.
biochemical:
- name: Serum follicle stimulating hormone
  notes: >-
    FSH rises into the menopausal range as follicular inhibin and estradiol feedback is
    lost. A single value above 25 IU/L in a woman under 40 with amenorrhea meets current
    international diagnostic criteria for POI.
  biomarker_term:
    preferred_term: Elevated circulating follicle stimulating hormone level
    term:
      id: HP:0008232
      label: Elevated circulating follicle stimulating hormone level
  evidence:
  - reference: PMID:39647506
    reference_title: "Evidence-based guideline: premature ovarian insufficiency(†)(‡)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "only one elevated follicle stimulating hormone (FSH) >25 IU is required for diagnosis of POI"
    explanation: >-
      Specifies the diagnostic threshold used for this biochemical marker. The threshold
      is defined for POI as a class.
- name: Serum anti-Mullerian hormone
  notes: >-
    AMH is produced by granulosa cells of small growing follicles and indexes ovarian
    reserve. It declines earlier than FSH rises, making it the more sensitive marker of
    the occult phase of FXPOI, and it is used where the POI diagnosis is uncertain.
  biomarker_term:
    preferred_term: Abnormal circulating antimullerian hormone concentration
    term:
      id: HP:0031101
      label: Abnormal circulating antimullerian hormone concentration
  cell_types:
  - preferred_term: granulosa cell
    term:
      id: CL:0000501
      label: granulosa cell
  evidence:
  - reference: PMID:39647506
    reference_title: "Evidence-based guideline: premature ovarian insufficiency(†)(‡)."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Questions were added on the role of anti-Müllerian hormone (AMH) in the diagnosis of POI"
    explanation: >-
      Documents the formal role of AMH in current POI diagnostic guidance. Graded
      INDIRECT because the guideline is not FXPOI-specific.
genetic:
- name: FMR1
  gene_term:
    preferred_term: FMR1
    term:
      id: hgnc:3775
      label: FMR1
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  association: >-
    A premutation-range CGG repeat expansion (55-200 repeats) in the FMR1 5' UTR at Xq27.3
    is the cause of FXPOI. The premutation, not the full mutation, confers the ovarian
    risk: full-mutation (>200 repeat) alleles are hypermethylated and silenced and cause
    fragile X syndrome rather than FXPOI. Risk within the premutation range is not
    monotonic in repeat length. It rises through the low-to-mid range, peaks at roughly
    70-100 repeats (highest at 85-89), and then falls away again at the largest premutation
    sizes, so that carriers below about 65 repeats and above about 120 repeats have no
    significantly increased risk relative to non-carriers. This inverted-U - the "FXPOI
    paradox" - is the most distinctive feature of FXPOI genetics and constrains any purely
    dose-dependent RNA-toxicity model (see discussions).
  evidence:
  - reference: PMID:33927378
    reference_title: Refining the risk for fragile X-associated primary ovarian insufficiency (FXPOI) by FMR1 CGG repeat size.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "women with 70-100 CGG repeats were at the highest risk for FXPOI using various statistical models to compare average age at menopause and risk of FXPOI, with women with 85-89 repeats being at the highest risk. Importantly, women with <65 repeats or >120 repeats did not have a significantly increased risk for FXPOI compared to women with <45 repeats."
    explanation: >-
      Large cohort study establishing the non-linear repeat-length risk relationship,
      including the fall in risk at the largest premutation sizes.
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the diagnosis of FXTAS or FXPOI is associated with a premutation-sized repeat (55-200 CGG repeats)"
    explanation: Establishes FMR1 premutation status as the genetic basis of FXPOI.
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FMR1 disorders include fragile X syndrome (FXS), fragile X-associated tremor/ataxia syndrome (FXTAS), and fragile X-associated primary ovarian insufficiency (FXPOI)."
    explanation: Places FXPOI within the FMR1 disorder spectrum attributable to this gene.
variants:
- name: FMR1 premutation CGG repeat expansion (55-200 repeats)
  description: >-
    An unstable CGG trinucleotide repeat expansion of 55-200 units in the FMR1 5'
    untranslated region. This range is normally spared the CpG-island hypermethylation
    that silences full-mutation (>200 repeat) alleles, so the premutation allele is
    transcribed - the basis for its gain-of-function pathogenicity in FXPOI and FXTAS. The
    allele is unstable on maternal transmission and can expand to a full mutation in
    offspring, which is the separate fragile X syndrome risk that dominates reproductive
    counseling for carriers. Two features reported to modify the allele's effect are not
    curated as evidence-backed claims here because their primary sources could not be
    fetched in this session: AGG interruptions within the CGG tract, which stabilize the
    repeat against intergenerational expansion but have not been shown to modify FXPOI
    risk in the carrier herself; and X-chromosome inactivation skewing, where preferential
    inactivation of the premutation-bearing allele is reported to be protective.
  gene:
    preferred_term: FMR1
    term:
      id: hgnc:3775
      label: FMR1
  type: trinucleotide_repeat_expansion
  clinical_significance: PATHOGENIC
  evidence:
  - reference: PMID:17618523
    reference_title: "Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "moderate expansions (55-200 repeats; premutation range) of a CGG trinucleotide in the fragile X mental retardation 1 (FMR1) gene"
    explanation: Defines the premutation allele class and repeat range.
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "more than 99% of individuals have a CGG expansion (>200 triplets) in the 5' UTR of the gene"
    explanation: >-
      Locates the repeat in the FMR1 5' UTR and gives the full-mutation threshold that
      bounds the premutation range above. The statement describes the full-mutation
      allele of fragile X syndrome rather than the premutation itself.
environmental:
- name: Tobacco use
  exposure_term:
    preferred_term: tobacco use
    term:
      id: ECTO:6000029
      label: exposure to tobacco smoking
  description: >-
    Tobacco use is an avoidable exposure in FMR1 premutation carriers because it lowers
    ovarian reserve and brings forward the age of onset of FXPOI. It is not a cause of
    FXPOI; it modifies the timing of a genetically determined process.
  presence: Modifier of onset timing
  effect: Deleterious - lowers ovarian reserve and advances age of onset
  evidence:
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FXPOI: tobacco use as this decreases ovarian reserve and the age of onset of FXPOI."
    explanation: >-
      GeneReviews lists tobacco under agents/circumstances to avoid for FXPOI, with the
      stated mechanism of reduced ovarian reserve and earlier onset.
diagnosis:
- name: FMR1 CGG repeat sizing
  description: >-
    Targeted molecular testing for the FMR1 CGG repeat (PCR-based repeat sizing with
    Southern blot as needed) is the definitive test. Standard multigene panels and
    exome or genome sequencing do not reliably detect the repeat expansion, so FMR1
    testing must be ordered specifically. FMR1 testing is a standard component of the POI
    diagnostic workup.
  evidence:
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The diagnosis of an FMR1 disorder is established through the use of specialized molecular genetic testing to detect CGG trinucleotide repeat expansion in the 5' UTR of FMR1"
    explanation: Identifies the specialized repeat-sizing assay as the diagnostic test.
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "typical multigene panels and comprehensive genomic testing (exome or genome sequencing) are useful only when no CGG repeat expansion is detected"
    explanation: >-
      Supports the caution that routine sequencing does not substitute for dedicated
      repeat sizing.
- name: Ovarian reserve assessment
  description: >-
    Serum AMH and antral follicle count on pelvic ultrasound, together with serum FSH and
    estradiol, index ovarian reserve and can detect the occult phase before amenorrhea.
    Serial rather than single measurements are informative because ovarian activity in
    FXPOI can fluctuate.
  evidence:
  - reference: PMID:39647506
    reference_title: "Evidence-based guideline: premature ovarian insufficiency(†)(‡)."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "guidance that AMH testing, repeat FSH measurement and/or AMH may be required where there is diagnostic uncertainty"
    explanation: >-
      Supports serial FSH and AMH testing in the diagnostic workup. Graded INDIRECT
      because the guideline covers POI generally and does not separately address antral
      follicle count.
- name: Karyotype and autoimmune workup
  description: >-
    Karyotype and adrenal/ovarian autoantibody testing are performed alongside FMR1 repeat
    sizing to exclude Turner syndrome, other X-chromosome abnormalities, and autoimmune
    oophoritis in a woman presenting with POI. These are exclusionary rather than
    confirmatory for FXPOI.
prevalence:
- population: Female FMR1 premutation carriers
  measure_type: LIFETIME_PREVALENCE
  prevalence_class: COMMON
  rate_per_100000: 20000.0
  notes: >-
    Approximately 20% of female FMR1 premutation carriers develop FXPOI, versus about 1%
    background POI prevalence. This is a within-carrier penetrance figure, not a
    population prevalence, and it derives largely from cohorts ascertained through fragile
    X families, which may overstate absolute risk among carriers identified by unselected
    population screening.
  evidence:
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FXPOI, defined as hypergonadotropic hypogonadism before age 40 years, has been observed in 20% of women who carry a premutation allele compared to 1% in the general population"
    explanation: Source of both the carrier-level figure and the general-population comparator.
differential_diagnoses:
- name: Primary ovarian insufficiency of other cause
  description: >-
    POI from any other cause presents with the same hypergonadotropic endocrine picture.
    Turner syndrome and other X-chromosome abnormalities, autoimmune oophoritis,
    iatrogenic causes (gonadotoxic chemotherapy, pelvic radiation, oophorectomy), and
    other monogenic POI genes are the main alternatives, which is why karyotype,
    autoantibody testing, and FMR1 repeat sizing are run together in the POI workup.
  distinguishing_features:
  - Absence of an FMR1 premutation on dedicated CGG repeat sizing.
  - Turner syndrome and other X-chromosome abnormalities are identified by karyotype.
  evidence:
  - reference: PMID:33495935
    reference_title: Fertility preservation for genetic diseases leading to premature ovarian insufficiency (POI).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "About 10% of cases of POI is related to genetic diseases. The most frequent conditions associated with POI are Turner syndrome and fragile X pre-mutation"
    explanation: >-
      Identifies Turner syndrome as the principal competing genetic diagnosis alongside the
      fragile X premutation.
- name: Fragile X syndrome
  disease_term:
    preferred_term: fragile X syndrome
    term:
      id: MONDO:0010383
      label: fragile X syndrome
  description: >-
    The full-mutation FMR1 disorder. It is caused by the same locus but by a different
    allele class and a mechanistically opposite lesion - hypermethylation and silencing
    with loss of FMRP, rather than transcription of a toxic expanded-repeat mRNA - and it
    does not carry the FXPOI ovarian phenotype.
  distinguishing_features:
  - Repeat size greater than 200 CGG with abnormal methylation rather than 55-200 unmethylated repeats.
  - Neurodevelopmental presentation with intellectual disability rather than an ovarian phenotype.
  evidence:
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "a definite diagnosis of FXS requires the presence of a full-mutation repeat size (>200 CGG repeats) while the diagnosis of FXTAS or FXPOI is associated with a premutation-sized repeat (55-200 CGG repeats)"
    explanation: States the allele-class distinction between fragile X syndrome and FXPOI.
- name: Fragile X-associated tremor/ataxia syndrome
  disease_term:
    preferred_term: fragile X-associated tremor/ataxia syndrome
    term:
      id: MONDO:0010382
      label: fragile X-associated tremor/ataxia syndrome
  description: >-
    The other premutation disorder. It shares the FMR1 premutation genotype and the RNA
    gain-of-function paradigm with FXPOI but affects the nervous system, presents in the
    seventh decade, and occurs in male as well as female carriers. FXTAS is a co-occurring
    risk in the same women rather than a competing explanation for their amenorrhea.
  distinguishing_features:
  - Late-onset progressive cerebellar ataxia and intention tremor rather than an ovarian phenotype.
  - Affects hemizygous male carriers, in whom FXPOI cannot occur.
  evidence:
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FXTAS occurs in individuals who have an FMR1 premutation and is characterized by late-onset, progressive cerebellar ataxia and intention tremor followed by cognitive impairment."
    explanation: >-
      Distinguishes the neurological premutation phenotype from the ovarian one on onset
      age, organ system, and affected sex.
treatments:
- name: Estrogen replacement therapy
  description: >-
    Systemic estrogen, with a progestogen in women with an intact uterus, is the mainstay
    of FXPOI management. It relieves vasomotor symptoms and mitigates the bone and
    cardiovascular consequences of premature estrogen deficiency, and is generally
    continued to the age of typical natural menopause. It does not restore ovarian
    function or fertility. Where FXPOI presents before puberty is complete, the same agent
    is used for pubertal induction before being continued as replacement.
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: sex hormone modifying agent therapy
    term:
      id: NCIT:C15445
      label: Hormone Therapy
    therapeutic_agent:
    - preferred_term: 17beta-estradiol
      term:
        id: CHEBI:16469
        label: 17beta-estradiol
    - preferred_term: progesterone
      term:
        id: CHEBI:17026
        label: progesterone
  target_phenotypes:
  - preferred_term: Hot flashes
    term:
      id: HP:0031217
      label: Hot flashes
  - preferred_term: Reduced bone mineral density
    term:
      id: HP:0004349
      label: Reduced bone mineral density
  target_mechanisms:
  - target: Chronic estrogen deficiency
    treatment_effect: BYPASSES
    description: >-
      Exogenous estrogen replaces the missing ovarian hormone output. It acts downstream of
      the follicle loss and does not correct the repeat-expansion lesion or restore the
      follicle pool.
  evidence:
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FXPOI: Gynecologic or reproductive endocrinologic evaluation can provide appropriate treatment and counseling for reproductive considerations and hormone replacement."
    explanation: GeneReviews names hormone replacement as the FXPOI management approach.
  - reference: PMID:39647506
    reference_title: "Evidence-based guideline: premature ovarian insufficiency(†)(‡)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although hormone therapy (HT) can mitigate some of these effects, many questions still remain regarding the optimal management of POI."
    explanation: >-
      Supports the mitigating effect of hormone therapy on POI sequelae while recording
      the residual uncertainty. The guideline addresses POI as a class.
  - reference: PMID:38677871
    reference_title: Primary Amenorrhea and Premature Ovarian Insufficiency.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pubertal induction and ongoing estrogen replacement therapy are often necessary."
    explanation: >-
      Supports both pubertal induction and continued estrogen replacement in
      hypergonadotropic POI. Graded INDIRECT because it is written for POI generally.
- name: Fertility preservation counseling and oocyte or embryo cryopreservation
  description: >-
    Because the timing of follicle depletion is unpredictable and the window closes
    permanently, women identified as premutation carriers should be counseled about
    fertility preservation early, while ovarian reserve remains. Oocyte or embryo
    cryopreservation is the established option once menarche has occurred. Efficacy in
    premutation carriers may be reduced by the ovarian changes that define the disorder,
    and ovarian tissue cryopreservation remains experimental in this population.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: Fertility Preservation
    term:
      id: NCIT:C71326
      label: Fertility Preservation
  evidence:
  - reference: PMID:33495935
    reference_title: Fertility preservation for genetic diseases leading to premature ovarian insufficiency (POI).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In case of spontaneous menarche (this can occur variably depending on the mutation) established techniques like embryo or oocyte cryopreservation can be proposed, even if, in some cases, their effectiveness may be reduced by ovarian alterations connected to the mutation."
    explanation: >-
      Supports oocyte and embryo cryopreservation as the established options in genetic POI
      and records the caveat on reduced effectiveness.
  - reference: PMID:33495935
    reference_title: Fertility preservation for genetic diseases leading to premature ovarian insufficiency (POI).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "If a diagnosis is issued before POI onset, counseling on currently available fertility preservation techniques is advisable."
    explanation: Supports counseling before onset as the intervention window.
- name: Donor oocyte in vitro fertilization
  description: >-
    For carriers who have already progressed to overt ovarian failure and wish to carry a
    pregnancy, donor oocyte IVF is the standard route, since it does not depend on the
    woman's own depleted follicle pool. It bypasses both the ovarian phenotype and the
    risk of transmitting an expanding FMR1 allele. No FXPOI-specific outcome evidence is
    cited here; this entry records standard practice.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: In Vitro Fertilization
    term:
      id: NCIT:C16580
      label: In Vitro Fertilization
- name: Bone health surveillance and protection
  description: >-
    Because premature estrogen deficiency accelerates bone loss, management includes bone
    mineral density monitoring alongside calcium and vitamin D sufficiency, with
    bone-protective pharmacotherapy reserved for established osteoporosis. Hormone therapy
    is the primary bone-protective measure; this entry covers the surveillance and
    adjunctive limb.
  action_category: MONITORING
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:39647506
    reference_title: "Evidence-based guideline: premature ovarian insufficiency(†)(‡)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The potential implications include adverse effects on quality of life, on fertility and on bone, cardiovascular and cognitive health."
    explanation: >-
      Establishes bone health as a management domain in POI. The guideline addresses POI
      as a class and this snippet does not specify a surveillance schedule.
- name: Tobacco avoidance
  description: >-
    Avoiding tobacco is specifically recommended in FMR1 premutation carriers because
    smoking further lowers ovarian reserve and brings forward the onset of FXPOI. It is
    the one modifiable exposure GeneReviews lists for FXPOI.
  action_category: COUNSELING_INFORMATIONAL
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FXPOI: tobacco use as this decreases ovarian reserve and the age of onset of FXPOI."
    explanation: >-
      GeneReviews lists tobacco under agents/circumstances to avoid for FXPOI, making
      avoidance the corresponding management action.
- name: Genetic counseling and reproductive genetic testing
  description: >-
    Counseling covers two distinct risks that must not be conflated: the woman's own risk
    of FXPOI and FXTAS, and the risk of transmitting an allele that expands to a full
    mutation and causes fragile X syndrome in offspring. Cascade testing of at-risk female
    relatives is standard, and prenatal or preimplantation genetic testing is available
    once the family allele is known.
  action_category: COUNSELING_INFORMATIONAL
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Mothers and their female relatives who are heterozygous for a premutation are at increased risk for FXTAS, FXPOI, and fragile X-associated neuropsychiatric disorders (FXAND)"
    explanation: Supports cascade testing of at-risk female relatives and the carrier's own risk counseling.
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible once an expanded (or altered) FMR1 allele has been identified in a family member."
    explanation: Supports the reproductive genetic testing options offered to carriers.
discussions:
- discussion_id: fxpoi_ovarian_mechanism_evidence_gap
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    By what intermediate steps does sequestration of CGG-repeat-binding proteins in
    granulosa cells lead to loss of the ovarian follicle, and does FMRpolyG add anything
    to the RNA arm that is already sufficient to kill granulosa cells?
  attaches_to:
  - pathophysiology#RNA gain-of-function and sequestration of CGG-repeat-binding proteins
  - pathophysiology#RAN translation and FMRpolyG production
  - pathophysiology#Granulosa cell dysfunction and death
  - pathophysiology#Accelerated ovarian follicle depletion
  rationale: >-
    The question of whether the FXTAS RNA-toxicity paradigm operates in granulosa cells at
    all is now substantially answered: an in vitro granulosa cell model shows expanded
    CGG-repeat RNA aggregating intranuclearly and killing granulosa cells, and a
    premutation mouse shows the corresponding RNA-binding proteins depleted in ovarian
    follicles. What remains open is the chain in between - which sequestered protein,
    acting on which granulosa function, translates into loss of a follicle - and whether
    FMRpolyG contributes anything additive, given that granulosa cell death does not
    require it. Three of the four nodes on this arm stay PROVISIONAL, for two different
    reasons: the RNA and RAN nodes because their direct evidence is still FXTAS-derived,
    and the granulosa node because its evidence, though ovarian, comes from an
    ectopic-expression cell model and from mice rather than from carriers. Only the
    follicle-depletion node is ESTABLISHED, since accelerated loss of ovarian reserve in
    premutation carriers is itself a clinical observation.
  proposed_experiments:
  - experiment_id: exp_fxpoi_granulosa_foci_fmrpolyg
    name: Repeat-RNA foci and FMRpolyG in premutation-carrier granulosa cells
    description: >-
      Assay granulosa cells recovered from FMR1 premutation carriers undergoing assisted
      reproduction for CGG-repeat RNA foci and FMRpolyG, and relate their burden to
      contemporaneous ovarian reserve markers (AMH, antral follicle count) and repeat
      length.
    supporting_outcome:
    - Detection of foci and FMRpolyG in granulosa cells recovered from premutation carriers themselves, scaling with repeat length and inversely with ovarian reserve, would replace the current ectopic-expression and mouse support with patient-derived evidence and justify moving the granulosa node from PROVISIONAL to ESTABLISHED.
    refuting_outcome:
    - Absence of foci and FMRpolyG in granulosa cells of affected carriers would argue that the ovarian lesion is not a direct transposition of the neuronal mechanism.
  - experiment_id: exp_fxpoi_ran_translation_dissection
    name: Separating RNA toxicity from RAN translation in granulosa cells
    description: >-
      In cultured human granulosa cells expressing premutation-length CGG repeats, block
      RAN translation without altering repeat-RNA abundance, and separately reduce
      repeat-RNA abundance while preserving FMRpolyG output, then measure cell viability.
    supporting_outcome:
    - Rescue on repeat-RNA reduction alone would establish RNA gain-of-function as the dominant ovarian arm.
    refuting_outcome:
    - Rescue only when FMRpolyG is blocked would reassign the ovarian mechanism to the RAN-translation arm.
- discussion_id: fxpoi_nonlinear_repeat_size_risk
  kind: OPEN_QUESTION
  status: OPEN
  prompt: >-
    Why is FXPOI risk non-linear in repeat length, rising through the mid-premutation range
    and then falling at the largest premutation sizes?
  attaches_to:
  - pathophysiology#FMR1 premutation CGG expansion and elevated FMR1 mRNA
  rationale: >-
    A purely dose-dependent RNA-toxicity model predicts that risk should rise monotonically
    with repeat length. The observed decline in risk at the largest premutation sizes is
    therefore a genuine constraint on the mechanism rather than a detail. The effect itself
    is no longer in question - it is curated in the genetic section on PMID:33927378, a
    1,668-carrier cohort - so what stays open here is the explanation, not the observation.
    The causal chain as curated has no node that would produce an inverted-U, and the usual
    proposal, that rising repeat-RNA burden is offset by falling translational output at
    the largest repeat sizes, has not been measured against ovarian outcome in the same
    carriers.
  proposed_experiments:
  - experiment_id: exp_fxpoi_repeat_length_stratified_molecular_profile
    name: Repeat-length-stratified FMR1 mRNA, FMRP, and FMRpolyG versus ovarian reserve
    description: >-
      In a carrier cohort stratified across the premutation range, measure FMR1 mRNA level,
      FMRP level, and FMRpolyG burden in the same individuals and relate each to ovarian
      reserve, testing whether declining FMRP or translational output at the largest repeat
      sizes offsets rising repeat-RNA burden.
    supporting_outcome:
    - An inverted-U in a composite toxicity measure that tracks the clinical risk curve would explain the non-linearity within the current model.
    refuting_outcome:
    - A monotonic molecular gradient across repeat lengths would indicate that the non-linear clinical risk arises outside the RNA-toxicity axis.
notes: >-
  Scope: this entry covers the ovarian phenotype of the FMR1 premutation. The neurological
  premutation phenotype is curated separately as Fragile X-Associated Tremor Ataxia
  Syndrome, and the full-mutation disorder as Fragile X Syndrome; the fragile
  X-associated neuropsychiatric disorders (FXAND) are not yet curated. MONDO:0010706 is
  labeled "premature ovarian failure 1" after OMIM 311360; the entry name follows current
  clinical usage (primary ovarian insufficiency), and the OMIM/MONDO label is retained as
  a synonym.

  Evidence provenance. Every snippet in this entry is now confirmed as an exact
  whitespace-normalized substring of its cited abstract. That confirmation came in two
  stages, which is worth recording because it shaped the entry. The bulk was verified
  locally against the committed reference cache. Eight further snippets, belonging to
  three FXPOI-specific papers added in response to PR review - PMID:36250920 (granulosa
  cell CGG-RNA toxicity), PMID:22470123 (CGG knock-in mouse follicle depletion), and
  PMID:33927378 (non-linear repeat-length risk) - could not be fetched or verified in the
  authoring session, because outbound access to NCBI E-utilities and every other
  literature host was blocked by network policy there. They were carried on the PR
  reviewer's verbatim quotes, with the PMIDs, titles and substantive claims independently
  corroborated by this entry's own deep-research report, and were then checked by CI.

  CI verified seven of those eight and rejected one: a penetrance sentence attributed to
  PMID:33927378 ("Approximately 20-30% of women with an FMR1 premutation experience
  FXPOI") is not present in that paper's abstract, though it may appear in the full text.
  That evidence item was removed rather than reworded, since the abstract could not be
  read from the authoring environment to source a correct quote. The prevalence claim it
  would have reinforced is unaffected - it still rests on the verified GeneReviews figure
  of 20% of carriers versus 1% of the general population - so what was lost is a
  corroborating primary-cohort citation, not the claim. Re-adding a correctly quoted
  penetrance figure from PMID:33927378 is a clean follow-up for anyone editing with
  network access. All three papers have since been fetched with `just fetch-reference`
  and their cache files committed, so verification no longer depends on a live fetch.

  A trap worth flagging for future editors: `unknown_prefix_severity: WARNING` in
  conf/reference_validator_config.yaml means an unfetchable reference is reported as a
  warning, not an error, and the runner treats warning-only results as success. A local
  `just validate` therefore prints "All validations passed" while silently skipping any
  snippet whose reference is not cached. Local green is not evidence of verification for
  an uncached PMID.

  Still deferred for the same reason: premutation carrier-frequency estimates, the
  AGG-interruption and X-inactivation-skewing modifier literature, and the mouse mTOR
  premature-follicle-recruitment result with its rapamycin rescue (a model-organism finding
  that must not be presented as a human treatment option). Depression and anxiety are
  described in the FXPOI literature as a principal morbidity domain alongside bone and
  cardiovascular health, but are not curated as phenotypes here for want of a verifiable
  snippet.

  Ontology limitation from the same cause: UBERON:0001305 (ovarian follicle) and
  GO:0003729 (mRNA binding) are the more precise terms for the follicle-depletion location
  and the RNA-toxicity molecular function, but neither is present in the committed
  dynamic-enum caches, and expanding them requires an ontology lookup that is unreachable
  from the authoring environment. UBERON:0000992 (ovary) is used instead and the
  molecular-function annotation is omitted; both should be tightened by anyone editing this
  entry with network access.
📚

References & Deep Research

References

1
PMID:20301558
FMR1 Disorders.
No top-level findings curated for this source.

Deep Research

1
Claude Code ▸
Fragile X-Associated Primary Ovarian Insufficiency (FXPOI): Comprehensive Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 37 citations 2026-07-31T00:20:52.542589

Fragile X-Associated Primary Ovarian Insufficiency (FXPOI): Comprehensive Research Report

1. Disease Information

Overview: Fragile X-associated primary ovarian insufficiency (FXPOI) is a chronic reproductive endocrine disorder in which women carrying a premutation-length CGG-repeat expansion in the FMR1 gene develop hypergonadotropic hypogonadism (oligomenorrhea/amenorrhea with elevated FSH and low estradiol) before age 40. It is one of three recognized clinical disorders on the FMR1-related spectrum — alongside Fragile X Syndrome (FXS, full mutation, >200 CGG repeats, transcriptional silencing) and Fragile X-associated Tremor/Ataxia Syndrome (FXTAS, premutation, late-onset neurodegeneration) — and is the leading known monogenic/inherited cause of idiopathic primary ovarian insufficiency (POI) in women.

Key identifiers: - OMIM: #311360 — Premature Ovarian Failure 1 (POF1), mapped to the FMR1 locus (OMIM gene 309550) at Xq27.3 - Orphanet: ORPHA:642691 — Fragile X-associated primary ovarian insufficiency - MedGen: CUI C4552079 — "Premature ovarian failure 1" - GeneReviews: FMR1 Disorders (NBK1384) — the umbrella clinical reference covering FXS/FXTAS/FXPOI - MeSH: Primary Ovarian Insufficiency (D016649); Fragile X Syndrome (D005600) as related term - Suggested MONDO term: a MONDO entry cross-referencing OMIM:311360/ORPHA:642691 (exact MONDO CURIE should be verified directly against the Mondo release, as web search did not resolve a stable ID) - ICD-10: E28.31 (Primary ovarian failure) is the closest coded diagnosis; there is no FXPOI-specific ICD-10/11 code — coding relies on the genetic diagnosis (FMR1 premutation) plus E28.31/E28.310

Synonyms: Fragile X-associated premature ovarian failure/insufficiency; FXPOI; Premature Ovarian Failure 1 (POF1); FMR1-premutation-associated POI.

Evidence base: Predominantly aggregated, disease-level clinical-genetics literature (cohort studies of premutation carriers ascertained through fragile X family studies, IVF/infertility clinics, and population-based carrier screening), supplemented by mouse and cell-culture (granulosa cell) mechanistic studies. Large population-based data (e.g., UK Biobank) are only recently becoming available and show smaller effect sizes than the highly ascertained fragile-X-family cohorts that dominate the literature (Morbey et al., Hum Reprod 2026).

2. Etiology

Disease Causal Factor — genetic (monogenic, X-linked, dosage/repeat-length dependent): FXPOI is caused by a premutation-range CGG trinucleotide repeat expansion (55–200 repeats) in the 5′ untranslated region (UTR) of FMR1 (fragile X messenger ribonucleoprotein 1, HGNC:3775, Xq27.3). Unlike the full mutation (>200 repeats) that causes FXS via CpG-island hypermethylation and transcriptional silencing, the premutation range remains largely unmethylated and is actively transcribed, producing a toxic gain-of-function at the RNA (and possibly protein) level rather than a straightforward loss of FMRP protein function.

Genetic risk factors: - CGG repeat number is the principal quantitative risk factor, but the relationship is non-linear ("inverted-U" / "FXPOI paradox"): risk rises through the low-to-mid premutation range and peaks around 70–100 repeats (highest risk at 85–89 repeats), then paradoxically declines at the largest premutation sizes (>100–120 repeats), approaching the risk of non-carriers (<45 repeats) at the extremes (Allen et al., Genet Med 2021, PMID:33927378; Elizur et al., PLOS ONE 2014, PMC4143194). This is proposed to reflect a balance between increasing toxic-RNA burden (rises with repeat length) and decreasing translational efficiency/FMRP output at very large premutation sizes (partial protective effect). - AGG interruptions within the CGG tract stabilize the repeat and reduce risk of intergenerational expansion, but do not show a clear association with age at amenorrhea/FXPOI risk itself (Mailick et al., PMC6086008) — distinguishing their role (relevant to FXS anticipation risk in offspring) from FXPOI risk in the carrier herself. - X-chromosome inactivation (XCI) skewing: preferential inactivation of the premutation-bearing X allele is associated with higher AMH / better ovarian reserve (protective), i.e., skewed XCI toward the normal allele attenuates the phenotype, analogous to its protective role in FXTAS/FXS severity (PMC5410032). - Modifier/susceptibility loci: genome-wide and candidate-gene studies (e.g., variation near ESR1, other menopause-timing loci identified via GWAS of natural menopause age) have been explored as modifiers of FXPOI onset age, though no single modifier gene has achieved the evidentiary weight of the FMR1 repeat length itself; this remains an active research area (PMC4124461, "Approaches to identify genetic variants that influence the risk for onset of FXPOI").

Environmental/other risk factors: No established non-genetic environmental cause; FXPOI is specifically the FMR1-premutation-attributable subtype of POI. General POI risk modifiers (smoking, pelvic radiation/chemotherapy, autoimmune disease) are not part of the FXPOI causal chain but are relevant differential/comorbid considerations (see Section 10).

Protective factors: - Genetic: shorter/longer-than-mid-range CGG repeat size (outside the 70–100 "risk zone"); skewed XCI toward the normal allele. - No established environmental/lifestyle protective factor specific to FXPOI has been robustly demonstrated in the literature retrieved.

Gene-environment interaction: Not well characterized for FXPOI specifically; the disorder is regarded as a highly penetrant-by-genotype (repeat-length-dependent) condition rather than one with strong documented GxE modulation.

3. Phenotypes

Core reproductive/endocrine phenotype (laboratory abnormality + clinical sign): - Oligomenorrhea/amenorrhea before age 40 — HPO: consider Amenorrhea (HP:0000141) / Oligomenorrhea (HP:0030041) - Hypergonadotropic hypogonadism — elevated FSH (>25 IU/L on two occasions ≥1 month apart, per consensus diagnostic criteria) and LH, with low estradiol — HPO: Hypergonadotropic hypogonadism (HP:0000815); Elevated circulating follicle stimulating hormone level (HP:0008232) - Hot flashes / vasomotor symptoms consistent with hypoestrogenism — HPO: Hot flashes (HP:0030788, if present) / general hypoestrogenism-related symptoms - Reduced/absent ovarian reserve — low AMH, low antral follicle count — HPO: Decreased ovarian reserve is not a distinct canonical HPO term in all releases; "Premature ovarian insufficiency" (HP:0008209) is the closest umbrella term - Infertility/subfertility — HPO: Female infertility (HP:0000786) - Primary or secondary amenorrhea with delayed puberty in the earliest-onset cases (reported as young as age 11) — HPO: Delayed puberty (HP:0000823), Primary amenorrhea (HP:0000786/HP:0000730 depending on release)

Onset/characteristics: - Age of onset: variable — mean age at menopause/amenorrhea in FXPOI is reported roughly a decade earlier than the general population (mid-30s to early 40s on average), with rare reported onset as early as 11 years old (primary amenorrhea/delayed puberty phenotype) through the usual definitional cutoff of 40 years. - Severity/course: highly variable and non-linear — menses may cease abruptly and permanently, or fluctuate irregularly for years before complete cessation ("occult" or intermittent ovarian insufficiency is common; some carriers retain intermittent ovulatory cycles even after FSH elevation). - Frequency among carriers: ~20% (range cited 20–30%) of FMR1 premutation carriers develop FXPOI, versus ~1% background POI prevalence in the general female population — i.e., a substantial relative-risk increase, though penetrance is incomplete and repeat-length-dependent (non-linear, see Section 2).

Downstream/associated phenotypes (estrogen-deficiency sequelae): - Reduced bone mineral density / early osteoporosis risk — HPO: Osteoporosis (HP:0000939) — via the osteoporosis_bone_resorption mechanism-module logic if curated in dismech - Increased cardiovascular risk (early estrogen loss) — general cardiovascular risk elevation, not a specific structural phenotype - Psychological impact: depression and anxiety related to infertility/hormonal loss — HPO: Anxiety (HP:0000739), Depressivity (HP:0000716) - Broader premutation-carrier comorbidities (not FXPOI-specific but co-occurring in the same genotype group under the umbrella "Fragile X Premutation Associated Conditions," FXPAC): FXTAS in later life (males and some female carriers), Fragile X-Associated Neuropsychiatric Disorders (FXAND: anxiety ~82%, ADHD ~66.5%, ASD ~32.8% in young carriers), autonomic dysfunction, hypertension, arrhythmia, neuropathy, thyroid autoimmunity, fibromyalgia/chronic pain (Movaghar et al./Hunter et al., PMC7578382; PMC9778214).

Quality of life impact: FXPOI carries a compound QoL burden — grief/loss related to infertility and premature reproductive aging, psychiatric comorbidity (anxiety/depression), and long-term health impacts of estrogen deficiency (bone, cardiovascular, possibly cognitive). The 2011 NFXF Clinical & Research Consortium consensus document explicitly identifies depression/anxiety, reduced bone mineral density, and increased cardiovascular risk as the three principal downstream morbidities requiring proactive management.

4. Genetic/Molecular Information

Causal gene: FMR1 (Fragile X Messenger Ribonucleoprotein 1; HGNC:3775; OMIM *309550; Xq27.3). Encodes FMRP, an RNA-binding protein regulating mRNA transport/translation at synapses (central to the FXS loss-of-function mechanism); FXPOI mechanism is distinct (see Section 6).

Variant/allele classification by CGG repeat number in the 5′ UTR: | Category | Repeat range | Methylation | Associated disease | |---|---|---|---| | Normal | ~5–44 | Unmethylated | None | | Intermediate/"gray zone" | 45–54 | Unmethylated | Uncertain; possibly mildly elevated risk of instability/subtle phenotypes | | Premutation | 55–200 | Typically unmethylated, transcribed | FXPOI, FXTAS, some FXAND | | Full mutation | >200 | Hypermethylated, silenced | Fragile X Syndrome |

  • Variant type: unstable trinucleotide (CGG) repeat expansion — not a missense/nonsense/structural variant in the conventional sense; classified functionally rather than via standard ACMG/AMP missense criteria. ClinVar/GTR entries for FMR1 repeat-expansion testing exist but classification is by repeat-length tier rather than a single pathogenic variant call.
  • Allele frequency / carrier frequency: Population estimates vary by ascertainment and ethnicity — pan-ethnic premutation carrier frequency roughly 1 in 200–300 women in several large carrier-screening cohorts (Owens et al. 2018 AJMG-A: 1 in 201; Genetics in Medicine 2011 national screening estimate ~1 in 148–178 in some cohorts), with a meta-analytic estimate as high as 1 in 129 women, and substantial regional/ethnic variation (e.g., ~1 in 600–777 in some Asian cohorts). Premutation prevalence is enriched in women ascertained specifically for POI (~2.0% in POI cohorts vs ~0.4% in unselected controls), underscoring FMR1 testing's diagnostic yield in POI workups.
  • Somatic vs germline: Germline, X-linked; the repeat is also somatically variable/mosaic in some carriers (repeat-length mosaicism is well documented across the FMR1 spectrum).
  • Functional consequence: Not classic loss-of-function; premutation-range transcripts show a toxic RNA gain-of-function (see Section 6), with a possible secondary contribution from repeat-associated non-AUG (RAN) translation producing an abnormal polyglycine-containing protein, FMRpolyG.

Modifier genes/factors: AGG interruption pattern (protects against intergenerational full-mutation expansion, not clearly protective for FXPOI onset itself); XCI skewing ratio (functionally modifies phenotype expression, not a "gene" per se but a key epigenetic modifier); candidate genome-wide modifiers of ovarian aging/menopause timing (under investigation, not yet definitively validated for FXPOI specifically).

Epigenetic information: Central to the FXS/FXPOI distinction — the full mutation triggers CpG-island hypermethylation and heterochromatinization silencing FMR1 transcription (causing FXS via FMRP loss), whereas the premutation range largely escapes this silencing, remains transcriptionally active (often with elevated mRNA levels relative to normal alleles due to reduced translational efficiency triggering a compensatory transcriptional upregulation), and it is this elevated/expanded transcript itself that is pathogenic in FXPOI.

Chromosomal abnormalities: Not applicable — FXPOI is a repeat-expansion disorder at a single locus, not a large-scale chromosomal rearrangement/aneuploidy (distinguishing it from Turner syndrome and other chromosomal causes of POI in the differential diagnosis).

Suggested gene/ontology annotations: Gene: hgnc:3775 (FMR1). Inheritance: X-linked, dominant with incomplete/age- and repeat-length-dependent penetrance (HP:0001417 X-linked dominant inheritance, or more precisely captured via the dismech Inheritance block with inheritance_term — note this is not classic digenic/oligogenic, but repeat-length is a genuinely graded/quantitative penetrance modifier worth capturing structurally).

5. Environmental Information

No specific environmental toxin, occupational exposure, or lifestyle factor has been established as a direct cause or major modifier of FXPOI in the literature surveyed — it is fundamentally a monogenic, repeat-length-dependent disorder. General POI risk factors that are not part of the FXPOI mechanism but are relevant to the broader differential diagnosis and comorbidity picture include: smoking (associated with earlier natural menopause generally), pelvic radiation, gonadotoxic chemotherapy (alkylating agents), and autoimmune conditions (autoimmune oophoritis, autoimmune polyglandular syndrome). No infectious agent is implicated in FXPOI.

6. Mechanism / Pathophysiology

FXPOI's pathophysiology is best understood as a graded causal chain from a genetic lesion to an organ-level clinical syndrome:

1. Trigger — Premutation CGG-repeat expansion (55–200 repeats) in FMR1 5′UTR → the expanded, largely unmethylated allele is actively transcribed, producing elevated levels of FMR1 mRNA containing the expanded CGG tract (2- to 8-fold increases reported in premutation carriers relative to normal-allele controls), while FMRP protein translation is relatively reduced/inefficient at larger repeat sizes (a partial loss-of-function component coexists with the dominant gain-of-function RNA mechanism).

2. Molecular mechanism — RNA toxic gain-of-function (leading hypothesis) ± RAN-translation protein toxicity (secondary/complementary hypothesis): - RNA toxicity: The expanded CGG-repeat-containing FMR1 mRNA forms intranuclear RNA aggregates/foci that sequester RNA-binding proteins essential for normal cellular function. In human granulosa-cell culture models, expanded CGG-repeat RNA accumulates in these intranuclear structures and causes significant granulosa-cell death independent of FMRpolyG expression, directly supporting an RNA-driven (not solely protein-driven) toxic mechanism (Rosario et al., FASEB J 2022, PMID:36250920). Specific granulosa-cell proteins sequestered by the CGG-RNA aggregates (e.g., FUS, PA2G4, TRA2β — shown reduced in ovarian follicles of an Fmr1 premutation mouse model) may become functionally deregulated as a consequence. - RAN translation / FMRpolyG: Repeat-associated non-AUG (RAN) translation of the expanded CGG repeat produces an abnormal, aggregation-prone polyglycine-containing protein, FMRpolyG, detected in premutation-carrier peripheral blood mononuclear cells and in FMR1-premutation granulosa cells, and proposed as a parallel/complementary toxic-protein mechanism to the RNA-aggregate pathway (PMC8951797; the "RNA or protein based?" debate is reviewed in Mila et al., Mol Hum Reprod 2020, PMC7566375). Current evidence favors RNA toxicity as necessary and sufficient for granulosa-cell death, with RAN-translation/FMRpolyG as a potentially contributing but non-essential secondary insult.

3. Cellular consequence — Granulosa cell dysfunction and death, altered folliculogenesis signaling: - Human granulosa cells cultured with CGG-repeat-expanded constructs show significant cell death (dose/repeat-length dependent, mirroring the human non-linear risk curve — worst around 80–120 repeats). - Premutation carriers show dysregulated AMH expression in mural granulosa cells and elevated FSH-receptor mRNA/protein — evidence of disrupted folliculogenesis signaling rather than simple follicle depletion alone (PMC8266831; PLOS ONE 2014 PMC4143194). - Mouse Fmr1-knockout studies additionally implicate premature activation/recruitment of the primordial follicle pool via increased mTOR/S6K signaling (i.e., accelerated "burn-through" of ovarian reserve rather than purely increased follicle death), with rapamycin (an mTOR inhibitor) reversing the accelerated-recruitment phenotype and preserving follicle numbers/reproductive lifespan in mice — a mechanistically and therapeutically important finding (Mok-Lin, Ascano, Serganov, Rosenwaks, Tuschl, Williams, Sci Rep 2018, 8:588, PMC5766488).

4. Tissue-level consequence — Accelerated ovarian follicle depletion: Knock-in mouse models carrying expanded CGG repeats (130, 90, and 100–199 CGG repeat lines have been generated) show normal establishment of the primordial follicle pool but a faster subsequent loss of follicles across all follicle classes (Hoffman et al., PMID:22470123), i.e., the lesion is in follicle maintenance/attrition rate, not initial pool formation — directly analogous to the human clinical picture of normal pubertal onset followed by accelerated reproductive aging.

5. Organism-level outcome — Depleted ovarian follicle population → hypergonadotropic hypogonadism (compensatory pituitary FSH/LH rise as negative feedback from declining estradiol/inhibin B) → amenorrhea, hypoestrogenism, infertility before age 40, with downstream estrogen-deficiency morbidity (bone loss, cardiovascular risk) and psychosocial impact.

Suggested ontology terms for pathophysiology nodes: - Gene/protein: hgnc:3775 FMR1 - Molecular process: GO:0006417 (regulation of translation); GO:0016556 (mRNA modification, if RAN-translation node is modeled); consider a free-text/qualifier for "RAN translation" and "RNA foci/aggregate formation" if no precise GO term exists - Cellular process: GO:0006915 (apoptotic process) for granulosa cell death; GO:0001541 (ovarian follicle development) for the folliculogenesis disruption node; GO:0008585 (female gonad development) - mTOR-related node (mouse mechanism): GO:0038202 (TORC1 signaling) - Cell type: CL:0000501 (granulosa cell) — primary cellular target; oocyte (CL:0000023) as the follicle unit ultimately depleted - Anatomical: UBERON:0000992 (ovary); UBERON:0001301 (ovarian follicle) - Downstream organism-level phenotype nodes: hypergonadotropic hypogonadism, amenorrhea, osteoporosis (could conforms_to the existing osteoporosis_bone_resorption module downstream of the estrogen-deficiency node), and potentially a cross-reference to cellular_senescence/accelerated-aging framing is not well supported by current evidence and should not be over-claimed — this is accelerated follicle attrition via a specific RNA-toxicity/mTOR-hyperactivation mechanism, not generic senescence.

Note on module fit for this codebase: Given dismech's existing renal_cystogenesis-style and hallmark-style module conventions, FXPOI's causal chain (repeat expansion → RNA toxic gain-of-function/RAN translation → granulosa cell death + mTOR-driven premature follicle recruitment → accelerated follicle depletion → hypergonadotropic hypogonadism) is a clean, atomic, well-evidenced chain suitable for direct pathophysiology modeling on the disease entry; it does not obviously need a new shared mechanism module unless curators identify other CGG-repeat RNA-toxicity disorders (e.g., FXTAS itself, or other repeat-expansion diseases) to lump under a shared "RAN-translation/RNA-foci toxicity" module — that would be a design decision for curators, not asserted here.

7. Anatomical Structures Affected

  • Primary organ: Ovary (UBERON:0000992), specifically the ovarian follicles (UBERON:0001301) and their constituent granulosa cells (CL:0000501) and oocytes (CL:0000023).
  • Secondary/systemic involvement (via estrogen deficiency):
  • Skeletal system — bone (reduced mineral density; UBERON:0002481 bone tissue)
  • Cardiovascular system — general elevated risk with chronic estrogen deficiency
  • Reproductive tract more broadly (uterus — atrophic changes with prolonged hypoestrogenism)
  • CNS/behavioral — psychiatric comorbidity (anxiety, depression), and note the co-occurring but mechanistically distinct CNS involvement of FXTAS in the same premutation-carrier population (cerebellum, particularly the middle cerebellar peduncles, in FXTAS — not part of FXPOI's own mechanism but frequently co-discussed in the same patients)
  • Tissue/cell level: granulosa cells (proliferative/steroidogenic support cells of the follicle) are the principal cellular target shown to undergo CGG-RNA-aggregate-induced death in vitro; oocytes are secondarily lost as the follicular unit is depleted.
  • Subcellular level: nucleus — intranuclear RNA aggregates/foci are the key subcellular pathological structure (GO Cellular Component: nucleoplasm, GO:0005654; consider "ribonucleoprotein complex," GO:1990904, for the RNA-foci structure specifically).
  • Localization: Bilateral, systemic (both ovaries affected as a consequence of a germline, X-linked genetic lesion present in all cells) — not a focal/lateralized process.

8. Temporal Development

  • Onset: Variable — typically manifests in the 3rd–4th decade of life (consistent with the "before age 40" definitional threshold), though case reports document ovarian insufficiency as early as age 11 presenting as primary amenorrhea/delayed puberty. Onset pattern is generally insidious/subacute — irregular cycles often precede frank amenorrhea by months to years ("occult" FXPOI with subclinical diminished ovarian reserve before FSH crosses the diagnostic threshold).
  • Progression: Not a classically staged disease, but conceptually: (1) normal pubertal onset and follicle pool establishment → (2) accelerated follicle attrition (subclinical/occult phase, detectable via declining AMH/antral follicle count) → (3) rising FSH with cycle irregularity → (4) hypergonadotropic amenorrhea meeting formal FXPOI criteria. Progression rate is variable between individuals and does not map cleanly onto repeat length alone (the non-linear repeat-risk curve, Section 2).
  • Disease course pattern: Can be abrupt and permanent cessation of menses in some carriers, or intermittent/fluctuating (menses "come and go" over years) in others before permanent cessation — an important counseling point since intermittent ovulatory function means spontaneous pregnancy remains possible even after a formal FXPOI diagnosis in some carriers, unlike typical post-menopausal ovarian failure.
  • Duration: Chronic, generally irreversible once established (analogous to natural menopause, just early), though the intermittent early phase is not necessarily permanent.
  • Remission: No treatment-induced remission of ovarian function itself exists; intermittent spontaneous ovulatory function (not true "remission") can occur, particularly in the earlier/occult phase.
  • Critical periods / intervention windows: The occult/pre-diagnostic phase (declining ovarian reserve markers, before permanent amenorrhea) is the key window for fertility-preservation counseling and family-planning decisions, since options (oocyte/embryo cryopreservation) are foreclosed after full follicle depletion. This is the central rationale for early FMR1 premutation identification (via family cascade testing or population carrier screening) well before clinical FXPOI onset.

9. Inheritance and Population

  • Epidemiology: FXPOI affects ~20% (range 20–30%) of female FMR1 premutation carriers, versus a background POI prevalence of ~1% in the general female population — making it, in aggregate, one of the more common identifiable monogenic contributors to POI once accounted for across the premutation-carrier population (though overall population-attributable incidence is limited by the premutation carrier frequency itself, ~1/130–1/300 women). A recent very large, less-ascertained UK Biobank analysis (~92,000 women; Morbey et al., Hum Reprod 2026) found that FMR1 repeat length increases POI risk from around 36 repeats onward but shows more modest effect sizes and limited incremental diagnostic utility over a polygenic menopause-timing score in an unselected population — an important caveat that most of the ~20–30% penetrance figures derive from highly ascertained fragile-X-family cohorts and may overstate absolute risk in unselected premutation carriers identified by population screening.
  • Inheritance pattern: X-linked, with the premutation transmitted from either parent but expansion-instability behavior occurring almost exclusively during maternal transmission (a male premutation carrier transmits the premutation to daughters essentially unchanged in size — a key feature distinguishing X-linked FMR1 transmission from typical X-linked dominant/recessive patterns). Penetrance for FXPOI itself is incomplete and quantitatively repeat-length-dependent rather than following simple dominant/recessive rules; a Mendelian dominant/incompletely-penetrant framing, structured as inheritance_term bound to an appropriate HPO mode-of-inheritance term (e.g., X-linked dominant inheritance, HP:0001423, with an explicit note on repeat-length-dependent, incomplete penetrance) is the closest fit, though curators should confirm the exact HPO term against the schema's controlled inheritance vocabulary.
  • Penetrance: Age- and CGG-repeat-size dependent (non-linear, peaking at 85–89 repeats; see Section 2); not fully penetrant even at maximal-risk repeat sizes.
  • Expressivity: Variable — from subclinical diminished ovarian reserve to primary amenorrhea in adolescence; modified by X-inactivation skewing.
  • Genetic anticipation: FXPOI itself does not show classic anticipation in the carrier, but the premutation allele is unstable and can expand to the full mutation (causing FXS) in offspring of female carriers — this is the central genetic-counseling anticipation concern for the FMR1 locus overall. Expansion risk is repeat-size dependent: 59–79 repeats expand to the full mutation in <50% of transmissions, while >90 repeats expand to full mutation in >90% of transmissions; AGG interruptions reduce expansion risk.
  • Germline mosaicism / somatic mosaicism: Repeat-length mosaicism across tissues is well documented for the FMR1 CGG tract generally.
  • Founder effects: Not prominently described for FXPOI-relevant premutation alleles specifically (contrast with some other repeat-expansion disorders); ethnic/geographic variation in premutation carrier frequency is more attributable to general population-genetic variation in repeat-length distribution than a single founder allele.
  • Consanguinity: Not a relevant risk factor (X-linked, repeat-instability mechanism, not recessive allele combination).
  • Carrier frequency: See Section 4 — approximately 1/129–1/300 women pan-ethnically, with substantial cohort/ethnicity-dependent variation; enriched (~2%) among women specifically ascertained for POI.
  • Population demographics: No strong published evidence of a specific geographically or ethnically restricted high-prevalence founder population for the premutation size range most relevant to FXPOI (contrast to some Ashkenazi-Jewish-enriched Mendelian conditions); sex distribution is exclusively female by definition (FXPOI is an ovarian phenotype), though male premutation carriers are relevant as unaffected-by-FXPOI transmitting parents and as an at-risk population for FXTAS. Age distribution of affected individuals spans adolescence (rare) through the late 30s (most common presentation window, given the <40-year diagnostic cutoff).

10. Diagnostics

Clinical/laboratory tests: - Diagnostic criteria (consensus): Absent menses ≥4 months plus menopausal-range serum FSH (>25 IU/L on ≥2 occasions ≥1 month apart) in a woman under age 40 with a known FMR1 premutation. - AMH (anti-Müllerian hormone): Reduced AMH is a useful earlier/screening marker of declining ovarian reserve, preceding overt FSH elevation ("occult" FXPOI detection); notably, premutation carriers show dysregulated (not simply low) AMH expression at the granulosa-cell level, an active mechanistic research area (PMC8266831). - FSH/LH, estradiol: standard hypergonadotropic hypogonadism labs (LOINC codes exist for FSH, LH, estradiol, AMH panels). - Pelvic ultrasound: antral follicle count, ovarian volume assessment. - Karyotype, adrenal/ovarian autoantibodies: performed as part of the standard POI diagnostic workup to rule out Turner syndrome and autoimmune oophoritis in the differential (ACOG Committee Opinion, "Primary Ovarian Insufficiency in Adolescents and Young Women," 2014).

Genetic testing: - First-line/definitive test: FMR1 CGG-repeat sizing by PCR/Southern blot (specialized fragile-X repeat-sizing assay, not standard NGS) — this is the specific test that establishes premutation-range (55–200 repeats) status and is the basis of the FXPOI diagnosis in a woman with clinical POI. - Recommended testing context: ACOG and ACMG-aligned guidance recommends FMR1 premutation testing as part of the standard POI diagnostic evaluation (alongside karyotype and autoimmune workup) in any woman diagnosed with POI, given the diagnostic yield (~2% of POI cases). - Cascade/family testing: once a premutation is identified in a proband (e.g., in the context of an FXS-affected child or FXTAS-affected relative), cascade testing of at-risk maternal relatives is standard practice for both FXPOI and reproductive/family-planning counseling. - AGG interruption analysis: increasingly offered alongside repeat sizing to refine offspring expansion-risk counseling (though not shown to refine FXPOI risk to the carrier herself). - Whole exome/genome sequencing, standard multi-gene NGS panels, chromosomal microarray, and karyotype are not the primary diagnostic modality for the FMR1 repeat expansion itself (repeat-expansion disorders generally require specialized repeat-sizing assays rather than standard short-read NGS, though long-read sequencing methods are emerging for repeat-expansion diagnostics broadly).

Differential diagnosis for POI presentation (before/alongside FMR1 testing): Turner syndrome and other X-chromosome abnormalities (karyotype), autoimmune oophoritis/autoimmune polyglandular syndrome (adrenal/ovarian antibodies, thyroid autoimmunity), iatrogenic causes (chemotherapy, pelvic radiation, oophorectomy), galactosemia (in the context of neonatal/early presentations), other rare monogenic POI genes (e.g., BMP15, FIGLA, NR5A1, FOXL2, mitochondrial POI genes), and secondary (hypothalamic-pituitary) causes of amenorrhea (which present with low/normal rather than elevated FSH, distinguishing "primary" ovarian from central causes).

Screening: No population-wide newborn or universal screening program for FXPOI specifically exists; the relevant screening context is (a) carrier screening in reproductive-age women (increasingly offered as part of expanded carrier screening panels, per ACOG guidance on FMR1 carrier screening), and (b) targeted testing of women presenting with POI or unexplained infertility/diminished ovarian reserve.

11. Outcome/Prognosis

  • Fertility/survival framing: FXPOI is not a mortality-associated condition per se; the "outcome" of clinical interest is reproductive (loss of fertility, timing of menopause) and long-term health (estrogen-deficiency morbidity), not survival.
  • Fertility outcomes: Loss of fertility before age 40, though — importantly — intermittent ovulatory function can persist even after formal FXPOI diagnosis in a subset of women (unlike natural post-menopausal ovarian failure), meaning spontaneous conception, while unlikely, is not impossible after diagnosis; this materially affects contraceptive and family-planning counseling.
  • Morbidity: Chronic estrogen deficiency drives the principal morbidity burden: reduced bone mineral density/early osteoporosis risk, increased cardiovascular disease risk (accelerated relative to women with typical-age menopause), and psychiatric morbidity (depression, anxiety related to infertility and hormonal loss) — explicitly identified as the three key morbidity domains in the 2011 NFXF consensus recommendations.
  • Quality of life: Significantly impacted by the combination of infertility-related grief, hormonal symptoms (vasomotor symptoms, mood), and (for many carriers) the broader family context of having/anticipating an FXS-affected child, compounding psychosocial burden beyond the ovarian phenotype alone.
  • Prognostic factors: CGG repeat size (non-linearly, per the risk curve), age at presentation, degree of X-inactivation skewing, and baseline/serial AMH trajectory are the main factors influencing individual prognosis and time-course, though no validated clinical prediction model exists to precisely forecast timing of complete ovarian failure for an individual carrier.
  • Recovery potential: No treatment reverses the underlying follicle depletion; hormone replacement addresses downstream estrogen-deficiency symptoms/morbidity but does not restore fertility.

12. Treatment

Pharmacotherapy (symptom/morbidity management, not disease-reversing): - Hormone replacement therapy (estrogen ± progestin) is the mainstay for managing vasomotor symptoms and — critically — for bone and cardiovascular protection in women with premature estrogen deficiency; standard POI management guidelines (extrapolated from general POI/HRT literature, as FXPOI-specific RCTs are limited) recommend HRT continued at least until the average natural age of menopause (~51 years) unless contraindicated. - Suggested MAXO/NCIT: NCIT:C15986 Pharmacotherapy + therapeutic_agent bound to CHEBI estrogen/progestin compounds (e.g., estradiol). - Bone health: calcium/vitamin D supplementation, DXA bone density monitoring, and bisphosphonates or other bone-protective agents in established osteoporosis, per general POI/osteoporosis management guidelines. - Psychiatric/psychological support: treatment of comorbid anxiety/depression (pharmacologic and psychotherapeutic) is explicitly recommended given the high burden of mood symptoms in this population.

Fertility-related interventions: - Fertility preservation (oocyte or embryo cryopreservation), ideally undertaken before significant ovarian reserve decline — i.e., as early as possible after a premutation is identified in a woman of reproductive age, given the unpredictable and sometimes rapid course of follicle depletion. MAXO term: consider MAXO:0000950 (supportive care) or a more specific reproductive-technology term if the schema supports it (fertility preservation is not cleanly covered by the standard MAXO treatment list referenced in this repo's CLAUDE.md; NCIT has more specific fertility-preservation procedure terms that should be looked up directly via OAK). - Donor oocyte IVF: standard option for carriers who have progressed to overt ovarian failure and desire biological pregnancy. - Preimplantation genetic testing (PGT) for carriers pursuing IVF, to select against full-mutation expansion in offspring — a reproductive-genetic intervention distinct from FXPOI treatment per se but highly relevant to the same patient population's family planning.

Experimental/emerging: - mTOR-pathway modulation (rapamycin): mouse model evidence (Mok-Lin et al., Sci Rep 2018) that rapamycin reverses premature primordial-follicle recruitment and preserves ovarian reserve in Fmr1-knockout mice is a promising preclinical, not yet clinically validated, therapeutic lead — explicitly a MODEL_SYSTEM_EXTRAPOLATION-type finding (per this repo's schema conventions) that has not been shown to translate to human FXPOI prevention/treatment; any dismech curation of this should be flagged as model-organism evidence only, not extrapolated to a human treatment recommendation. - No FMR1-targeted gene therapy, RNA-targeted therapy (e.g., ASO), or disease-modifying pharmacotherapy specific to FXPOI has reached clinical use or late-stage trials based on the literature surveyed; this remains an area of active preclinical mechanistic research (RNA-toxicity-targeted approaches are conceptually plausible given the RAN-translation/RNA-foci mechanism but not yet clinically developed for FXPOI specifically).

Treatment strategy: Management is fundamentally supportive/preventive rather than curative — early identification (via FMR1 testing in POI workups or cascade/carrier screening), proactive fertility-preservation counseling before reserve is lost, HRT for symptom control and long-term bone/cardiovascular protection, and psychiatric screening/support, per the NFXF Clinical & Research Consortium's 2011 consensus and later updates (5th International Conference on FMR1 Premutation recommendations, PMC10529056).

13. Prevention

  • Primary prevention of FXPOI itself (preventing the genetic lesion) is not possible — it is a germline genetic condition; "prevention" in practice means preventing its downstream consequences through early detection.
  • Secondary prevention (early detection): Identification of FMR1 premutation carrier status before onset of clinical FXPOI — via (a) cascade testing of at-risk female relatives of a known fragile-X family, or (b) expanded reproductive/prenatal carrier screening — enables anticipatory fertility-preservation counseling and family-planning decisions while ovarian reserve is still adequate.
  • Genetic counseling: A central preventive/management tool — carriers should receive counseling on (a) their own FXPOI risk (repeat-length-informed, though imprecise for an individual), (b) offspring expansion-to-full-mutation risk (repeat-size- and AGG-interruption-informed), and (c) reproductive options including prenatal diagnosis or PGT.
  • Tertiary prevention (preventing complications once FXPOI has occurred): HRT to prevent/mitigate osteoporosis and cardiovascular disease, bone density monitoring, and mental health screening/support — i.e., preventing the downstream morbidity of established ovarian insufficiency, per the consensus management recommendations discussed in Section 12.
  • Screening programs: No population-wide newborn screening; the relevant screening is targeted reproductive carrier screening (increasingly included in expanded carrier-screening panels) and diagnostic-context testing of women presenting with POI/infertility.
  • Public health/environmental interventions: Not applicable — no environmental exposure to mitigate.

14. Other Species / Natural Disease

  • No naturally occurring veterinary/companion-animal analog of FXPOI has been identified in the literature surveyed (unlike Fragile X Syndrome, for which no robust natural-disease animal counterpart exists either — the condition is modeled exclusively via engineered genetic models, not naturally occurring animal disease).
  • Orthologous gene: Fmr1 is highly conserved; mouse Fmr1 (MGI:95523) is the standard ortholog used for modeling (NCBI Gene mouse Fmr1: Gene ID 14265).
  • No OMIA (Online Mendelian Inheritance in Animals) entry for a natural CGG-repeat-expansion ovarian insufficiency disorder was identified — this is expected, as trinucleotide-repeat instability disorders of this type are essentially unique to the human FMR1 locus's particular repeat architecture and are not known to occur naturally in veterinary species.
  • Comparative biology: FMRP function and the RNA-binding/translational-regulation biology are broadly conserved across mammals, supporting the validity of mouse knock-in models for mechanistic study (see Section 15), though no spontaneous/natural veterinary disease exists to compare.

15. Model Organisms

Genetic mouse models (knock-in, the dominant model system for FXPOI mechanism research): - CGG-repeat knock-in mice: at least three independently generated knock-in lines carrying expanded CGG repeats in the murine Fmr1 5′UTR — commonly cited repeat sizes include ~130 CGG repeats, ~90 CGG repeats, and a 100–199 CGG repeat line — used to model the premutation state and its RNA-toxicity consequences in vivo. - Key phenotype recapitulation: normal establishment of the primordial follicle pool (i.e., the initial reproductive endowment is unaffected) but an accelerated rate of follicle loss across all follicle classes, closely mirroring the human clinical pattern of normal puberty followed by premature reproductive aging (Hoffman et al., PMID:22470123). - Reduced expression of specific RNA-binding proteins (FUS, PA2G4, TRA2β) demonstrated in ovarian follicles of a premutation knock-in mouse model, supporting the human granulosa-cell RNA-sequestration mechanism. - Fmr1-knockout (null) mice (a distinct, loss-of-function-only model, not repeat-expansion "premutation" per se) also show premature recruitment of the primordial follicle pool via increased mTOR/S6 kinase activity, with rapamycin reversing the phenotype — this specific mechanistic lead (mTOR hyperactivation → premature follicle recruitment) currently derives from the knockout rather than repeat-expansion knock-in model, an important nuance: the mTOR-hyperactivation mechanism observed in Fmr1-null mice may reflect FMRP loss-of-function rather than the CGG-repeat-RNA gain-of-function mechanism thought to dominate the human premutation/FXPOI phenotype, so translational applicability of the rapamycin finding specifically to human FXPOI (a gain-of-function-driven condition) should be considered with appropriate caution — an explicit HUMAN_MODEL_MISMATCH-type caveat if curated in dismech, since the knockout model isolates loss-of-FMRP-function whereas human FXPOI is attributed primarily to premutation-range RNA toxicity, a mechanistically distinct (though possibly convergent, via mTOR) pathway.

In vitro / cellular models: - Human granulosa-cell culture models transfected with expanded-CGG-repeat FMR1 constructs are the key human-cell system directly demonstrating CGG-RNA-aggregate-induced granulosa cell death, independent of FMRpolyG — the most direct human-tissue-relevant mechanistic evidence available (Rosario et al. 2022; earlier work in Fertility and Sterility establishing the original "RNA toxic gain-of-function" granulosa-cell model). - Patient-derived granulosa cells obtained from IVF cycles of premutation carriers have been used directly (not just engineered cell lines) to show elevated FMR1 mRNA, dysregulated AMH, and elevated FSH-receptor expression correlating with reduced oocyte yield — a valuable "natural human cellular model" complementing the engineered systems.

Model limitations: Mouse models recapitulate the accelerated-follicle-loss phenotype well but do not fully capture the human non-linear ("inverted-U") repeat-length risk curve in vivo across a matched range of repeat sizes within a single study, nor the full spectrum of human FXAND/psychiatric comorbidity; and as noted above, the mechanistically important mTOR/rapamycin finding derives from a null (knockout) rather than repeat-expansion (knock-in) model, creating a translational-validity gap between the proposed therapeutic lead and the actual human disease mechanism that should be flagged rather than assumed resolved.

Applications: These models are used to dissect (a) RNA- vs protein-mediated toxicity, (b) the follicle-pool-establishment-vs-attrition-rate question, (c) candidate therapeutic targets (mTOR pathway), and (d) sequestered-protein identification (FUS, PA2G4, TRA2β) as downstream biomarker/mechanism candidates.

Summary Table for Curation

Domain Key value
Gene FMR1, HGNC:3775, Xq27.3
Causal lesion CGG-repeat premutation expansion, 55–200 repeats, 5′UTR
OMIM #311360 (POF1)
Orphanet ORPHA:642691
Penetrance in carriers ~20% (20–30%), non-linear by repeat size, peak risk 85–89 repeats
Background POI prevalence ~1%
Diagnostic criteria Amenorrhea ≥4 mo + FSH >25 IU/L ×2, age <40, known FMR1 premutation
Core mechanism CGG-repeat RNA toxic gain-of-function (intranuclear RNA foci) ± RAN-translation FMRpolyG → granulosa cell death + mTOR-driven premature follicle recruitment → accelerated follicle depletion
Key cell type Granulosa cell (CL:0000501)
Key organ Ovary (UBERON:0000992)
Treatment Symptomatic/preventive: HRT, fertility preservation, bone/cardiovascular monitoring, psychiatric support; no disease-modifying therapy

Sources